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ABSTRACT
Kisspeptins, peptide products of KISS1, are endogenous ligands for
KISS1R, a G protein-coupled receptor. In numerous cancers, KISS1 acts as a
metastasis suppressor. However, studies have revealed that patients with
elevated KISS1 and KISS1R breast tumor expression have increased tumor
grade, increased lymph node metastases and poor survival. We hypothesize that
depletion of KISS1R inhibits breast cancer cell metastasis. In order to assess the
role of KISS1R in breast cancer metastasis, we used a pre-clinical orthotopic
xenograft mouse model using MDA-MB-231 breast cancer cells for breast tumor
establishment. We discovered that depletion of KISS1R decreased primary tumor
growth and reduced lung metastatic burden, suggesting that KISS1R plays a role
in promoting breast cancer metastasis. Furthermore, we observed that
kisspeptin-10 stimulation increased breast cancer cell invadopodia formation via
a β-arrestin2 dependent mechanism. Overall, our results suggest that KISS1R
may be a novel therapeutic target in the prevention of breast cancer metastasis.
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Chapter 1- Introduction
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1.1.1 Breast Cancer Staging and Classification
According to the Breast Cancer Society of Canada, breast cancer is the
most diagnosed cancer in Canadian women over the age of 20 and the second
leading cause of Canadian women cancer related deaths†. In 2013, 23 800
Canadian women were diagnosed with breast cancer representing 26% of all
diagnosed cancers in Canadian women†. Additionally, approximately 5000
women in Canada died from breast cancer, accounting for 14% of all cancer
related deaths†. Due to the high rates of incidence and death to Canadian
women, it is clear that a better understanding of breast cancer is required in
order to develop better therapeutics and clinical strategies to combat the disease.
Breast cancer staging assesses the extent cancer has developed within
the body and whether the cancer has spread to other tissues (Figure 1.1) (1).
The American Joint Committee on Cancer (AJCC) has developed a system of
breast cancer classification based on tumor origin, cellular characteristics and
metastatic extent. Stages I-III are classified based on the range of initial primary
tumor size and the extent of breast cancer cell spread to lymph nodes that
surround the breast (1). Most often, breast cancer arises from breast epithelium
in either ductal or lobular tissue of the mammary glands and is termed ductal
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), respectively (2). In
situ refers to non-invasive breast cancer in which the tumor is confined to the
milk duct or lobules of the breast. At this point the tumor cells are confined to the
tissue and are not a threat of undergoing metastasis and thus classified as
benign hyperplasia. Cells in DCIS and LCIS demonstrate an increased number of

3
anaplastic and mitotic cells, pleomorphism, and central luminal necrosis due to
lack of blood supply (3). As cancer progresses and begins to invade into the
surrounding tissue, they are then classified as invasive and pose a great risk to
metastasis. The most common invasive breast cancers are ductal carcinoma
(IDC) and invasive lobular carcinoma. These cancers often demonstrate lymph
node metastases. The final stage, Stage IV, represents breast cancer that has
metastasized to distant organs, such as bone, lung and brain, at which point the
cancer becomes inoperable and lethal (1, 4).
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Figure 1.1. The steps of breast cancer progression. Non-malignant epithelial
cells proliferate uninhibited leading to ductal hyperplasia. Epithelial cells lose
their normal phenotype as well as morphology and begin to assume an
expression profile of mesenchymal cells indicative of carcinoma advancement.
Ultimately, cancer cells will acquire the ability to invade and migrate into the
surrounding tissue initiating metastasis.
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1.2.1 Metastatic Cascade
Metastasis is the process by which cancer cells leave the primary tumor
and disseminate to secondary sites within the body either through the blood
circulatory system, the lymphatic system or within body cavities (Figure 1.2)(5).
When breast carcinomas are confined to breast tissue, 5-year survival rates
exceed 90% (6). However, long-term survival is significantly decreased when
cancer cells metastasize and survival time is adversely affected depending on
the extent and sites of colonization (7). The initial step of the metastatic cascade
involves a subpopulation of non-malignant cells accumulating mutations causing
a malignant phenotype (8). In the context of breast cancer carcinoma, a tumor
develops when epithelial cells undergo malignant transformation resulting in
increased cellular proliferation and cell survival (9). Cancer cell survival is
achieved through the development of anchorage independent growth and
evasion of apoptotic signaling (5).
Angiogenesis, the process of new blood vessel formation from previous
vasculature, is an important event that regulates tumor growth and survival (10).
Under normal physiological conditions, angiogenesis plays an important role in
wound healing, placentation during pregnancy and in utero cell proliferation
during the female reproductive cycle (11). Angiogenesis is precisely controlled
through a balance of pro- and anti-angiogenic factors. In disease, this balance of
pro- and anti-angiogenic growth factors is lost. In cancer, a plethora of proangiogenic factors are released inducing tumor-associated microvasculature
(12). This tumor-associated microvasculature is essential for tumor growth and
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survival for the new blood vessels supply nutrients and oxygen that regulates
tumor

growth

and

size

(13).

Thus,

the

amount

of

tumor-associated

microvasculature, or tumor microvessel density, is used as a prognostic marker
for cancer stage and progression (14, 15). In these circumstances, blood vessel
formation can arise from pre-existing vasculature from the host or originate from
the cancers cells themselves in a process known as vascular mimicry (16). The
molecular events underlying angiogenesis are stimulated under hypoxia
conditions. As tumors increase in size, the availability of oxygen for each
individual cell becomes exhausted and results in a hypoxic state. Under hypoxic
conditions, the hypoxia inducible factor-1 (HIF-1) transcriptional complex
becomes activated and induces promotion of pro-angiogenic factors, apoptotic
resistance, anaerobic metabolism, and resistance to apoptosis (17). The vascular
epithelial growth factor (VEGF) is a pro-angiogenic factor that has been
demonstrated to play an important role in cancer induced angiogenesis. VEGF is
created by tumor cells themselves or is released from the degradation of
extracellular matrix (ECM) that surrounds the tumor (10). VEGF will then diffuse
into the surrounding tissue and bind to VEGF receptors on the endothelial cells of
pre-existing blood vessels, stimulating endothelial cell proliferation (10). The new
endothelial cells form new networks of immature vessels within and surrounding
the tumor. Often these immature vessels are fenestrated providing an opportunity
for cancer cell metastasis (8).
Initial cell spreading or dissemination occurs in a process known as
epithelial-to-mesenchymal transition (EMT), where epithelial cells lose cell-to-cell
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adhesion, lose cellular polarity, and gain a mesenhymal phenotype of invasion
and migration (18). Under normal physiological conditions, epithelial cells are
organized in continuous sheets of polarized cells conveyed by cell-cell
connections accomplished by gap and tight junctions, desmosomes, and
adherens junctions (19). Furthermore, epithelial cells demonstrate an apicalbasolateral polarity organization which prevents individual cells from migrating.
During EMT, epithelial cells will lose cellular polarity and cell-cell contact via
deceased expression of important adhesion molecules such as E-cadherin (20).
Concurrently, an increase in mesenchymal markers is observed. These markers
include matrix metalloproteases (MMP), N-cadherin, vimentin, β-catenin, and
Snail/Slug conferring a highly mobile disorganized cellular morphology (18). Cells
which undergo EMT migrate away from the primary tumor through cellular cycling
of adhesion/ de-adhesion molecules regulated by integrins and the formation of
F-actin stress fibers through which myosin cycling initiates movement (5).
In combination with cell migration, cancer dissemination requires cells to
invade through the underlying basement membrane, that surrounds the tumor,
and into the surrounding ECM (8). For invasion to occur, the tumors cells must
induce ECM remodeling to allow movement of the cancer cell. Cancer cells
secrete several proteases that confer ECM remodeling (21). The most common
proteolytic enzymes involved in metastasis are MMPs, cathepsins and urokinasetype plasminogen activators (uPA) (21-23). Activation of these proteases during
cancer metastasis results in uncontrolled degradation of the basement
membrane and ECM. The degradation of ECM results in the release of growth
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factors such as the epidermal growth factor (EGF) and VEGF, further contributing
to local angiogenesis and metastatic progression (24).
After the tumor cells have invaded and migrated through the basement
membrane and surrounding stromal compartment, they will reach the newly
formed tumor-associated microvasculature formed through the angiogenesis
process. Due to the highly fenestrated nature of these vessels, tumor cells can
enter the blood vessels through the event known as intravasation (24). Tumors
cells will bind to endothelial cells inducing endothelial cell retracting and tumor
cell entrance into cardiovascular circulation (24). Additionally, tumor cells may
enter circulation through the lymphatic system. Due to the lack of tight junctions
between endothelial cells in the lymphatic system, as opposed to the
cardiovascular system, tumor cells may pass more easily through lymphatic
endothelial cells (8). Once in cardiovascular or lymphatic circulation, tumor cells
must survive by evading immune system destruction. One mechanism of survival
is achieved through tumor cell clumping with other cells to help to create a
physical barrier from the immune system (25). This clumping can occur with
other cancer cells or with cells of the circulation system, such as blood platelets
(24). At distant sites within the body, the cancer cells arrest in capillary beds,
bind to endothelial cells and enter surrounding tissue in the process of
extravasation (26). Metastasized cells may undergo apoptosis, however the few
that survive can lay dormant for an extended length of time or proliferate
immediately establishing a secondary tumor site (27). Similar to primary tumor
growth, the secondary tumor requires angiogenesis to supply the growing tumor
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and may act as a barrier to secondary tumor proliferation if angiogenesis cannot
be induced (27). Once secondary tumors are established successful medical
intervention is limited and the lethal effects of cancer result. It is proposed that if
a cancer cell cannot complete any step of the metastatic cascade, metastasis will
be inhibited. However, due to the number of complementary molecular signaling
pathways that are involved in each step of metastasis, identifying effective
therapeutic targets remains a challenge (8).
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Figure 1.2. The metastatic cascade. In order for cancer cells to spread to
distant tissues, they must undergo several events that make up the metastatic
cascade. The initial step is the formation of the primary tumor through
proliferation of cancer cells (i). As the tumor progresses, some cancer cells will
leave the primary tumor through invasion and migration into the surrounding
tissue (ii). Tumor cells stimulate the formation of new blood vessels enabling
tumor growth (iii). Eventually, some cancer cells will enter blood vessels through
intravasation (iv) and survive in circulation (v). At distant tissues some cancer
cells will leave blood vessels through extravasation (vi) and colonize at
secondary sites (vii). Adapted from Valastyan et al. (2011) (28)
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1.2.2 Invadopodia
The ability of cancer cells to metastasize is dependent on the formation of
the cellular structure known as invadopodia. Invadopodia are actin rich
membrane protrusions formed on cancer cell surfaces that contribute to invasion
through focal delivery of proteases (29). Structurally, invadopodia are recognized
as punctate actin structures on the ventral surface of cells with co-localization of
cortactin and associated underlying degradation (30). In vivo evidence
demonstrates that invadopodia formation is directly involved in primary tumor
invasion of the underlying basement membrane and ECM (31, 32). Furthermore,
when invadopodia formation is inhibited, cancer metastasis is inhibited through
the reduction of cancer cell intravasation and extravasation (31, 32).
Invadopodia formation occurs through several stages from initial formation
to final maturity. Each stage of invadopodia is dependent on the coordinated
activation and localization of several proteins (Figure 1.3). Invadopodia formation
is stimulated by various growth factors, such as the epidermal growth factor,
leading to the invadopodia precursor organization (29, 33, 34). The invadopodia
precursors are involved with binding to actin and inducing actin polymerization
forming the invadopodia structure (35). The first major invadopodia precursor
involved is the actin binding protein known as cofilin, which functions to cleave
actin filaments to create new barbed end actin formations (36). Theses actin
barbed end formations provide sites for actin polymerization and invadopodia
extension (36). Two primary mechanisms of cofilin regulation have been
proposed. The first mechanism involves blocking the binding of cofilin to actin via
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serine phosphorylation at residue 3 by LIM-kinase 1 (37). The second
mechanism is blocking cofilin’s ability to bind to actin through the binding of
phosphorylated cortactin to cofilin (38). The second major invadopodia precursor
is cortactin. Cortactin’s function is to promote invadopodia formation through
actin binding and complexing with Arp2/3-N-WASP-dynamin, to promote actin
polymerization and invadopodia protrusion (32). Cortactin is a major Src
substrate where several tyrosine residues act as on/off switches for cortactin
activity. Src phosphorylation at residues Y421, Y466, and Y482 act as an
inhibitory mechanism by inhibiting the interaction and activation of N-WASP (39,
40). When the mechanism of cofilin and cortactin control goes unchecked,
invadopodia formation is favored, promoting cancer cell invasion and metastasis
(41). Finally, invadopodia maturation occurs when the invadopodia acquire its
matrix degradation ability.
The invasive ability of invadopodia is mediated by the membrane bound
matrix degradation protein, MT1-MMP. An accumulation of MT1-MMP occurs in
invadopodia which in turn degrades the extracellular matrix (ECM) and basement
membrane components including fibronection, laminins 1 and 5 and collagen I, II,
and III (42). In vitro studies have demonstrated that MT1-MMP is required for
cancer cell migration and invasion through Matrigel, an ECM mimetic (43).
Furthermore, MT1-MMP, as opposed to MMP-2 or MMP-9, is responsible for
invasion of cancer cells through the basement membrane, establishing an
essential role for MT1-MMP in the initiation of metastasis (44). Upon invadopodia
stimulation and formation, newly synthesized or recycled MT1-MMP molecules
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are delivered to the invadopodia tip. The scaffolding protein IQGAP1, which
provides a link between microtubule and actin cytoskeleton networks,
coordinates vesicle-tethering of the exocyst complex for MT1-MMP surface
delivery (45, 46). Upon activation of small GTPase RhoA, IQGAP1 complexes
with the exocyst vessel containing MT1-MMP providing focal degradation (45).
Whether MT1-MMP activity can be stimulated by receptors is unknown and is a
focus of this study.
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Figure 1.3. Invadopodia formation and activity. Growth factor stimulation
induces invadopodia formation through invadopodia precursor organization.
Cofilin initiates actin polymerization by severing actin filaments to generate free
actin barbed ends (i). Cortactin binds to actin filaments at actin barbed end
formations and favors actin polymerization by recruiting the N-WASP Arp2/3
complex (ii). MT1-MMP is transported to the invadopodia tip by microtubule
vesicle trafficking and IQGAP1 coordinates exocyst release of MT1-MMP onto
the invadopodia surface (iii). MT1-MMP causes extracellular matrix degradation
facilitating cellular invasion.
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1.3.1 Metastasis Suppressor Genes
Breast tumorgenesis, the transformation of non-malignant cells to cancer
cells, begins in breast cells of varying types and due to either genetic or
environmental factors inducing a malignant change (47). The cancer cells exhibit
specific characteristics not seen in non-malignant cells such as loss of
differentiation, loss of apoptotic signaling, promotion of angiogenesis, loss of cellcell contact, evasion of host immune system, and immortalization (47). It has
been proposed that cancer arises from the accumulation of mutations in genes
that affect key cellular pathways involved in growth and development leading
malignant capacity (48). These alterations can occur within malignant cells or
within host cells that surround malignancy such as vascular or immune cells (47,
49). Recently, a new classification of genes have been discovered which are
involved in tumor progression as opposed to tumor initiation. These genes are
known as metastasis activator and metastasis suppressor genes. Unlike
oncogenes or tumor suppressor genes, metastasis activator or suppressor genes
do not affect the primary tumor tumorgenicity, but instead are involved in the
ability of cancer cells to metastasize to distant tissue areas (50). Several
metastatic suppressor genes have been identified whose expression have shown
to disrupt the metastatic cascade, rendering metastatic cells non-metastatic. A
few examples are NME1, MKK4, KAI1, E-cadherin, and KISS1 (51). Due their
ability to inhibit metastasis without blocking primary tumor growth, metastasis
suppresser genes provide a promising option for the development of therapeutic
strategies in the prevention of metastatic disease.
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1.3.2 KISS1 and KISS1R Discovery
KISS1, a metastasis suppressor gene, was originally identified by Lee and
colleagues in 1996 (50). To investigate what governs the ability of cells to
undergo metastasis, Lee and colleagues used subtractive hybridization to
determine the gene expression differences between two melanoma cell lines, the
non-metastatic neo6/C8161.1 and metastatic cells C8161. Lee and colleagues
discovered that an unidentified cDNA sequence encoding for a 164 amino acid
protein was amplified in the non-metastatic neo6/C8161.1 cell line in comparison
to the metastatic C8161 cell line (50). This unknown cDNA was termed KISS1
gene. Since then, studies have shown KISS1 mRNA expression in the placenta,
testis, brain, pancreas, liver, ovaries, small intestine, heart, skeletal muscle,
breasts, kidneys, and lungs (52, 53). KISS1 gene encodes a 145 amino acid
peptide that is cleaved to 10, 13, 14, or 54 amino acid lengths (53, 54). These
secreted proteins are called kisspeptins (KP) and the smallest active form KP-10,
is comprised of the amino acid sequence H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-LeuArg-Phe-NH2 (55). This sequence is conserved over an assortment of species,
differing from the human sequence by a single amino acid in sheep, mouse, rat,
and cow (56). Using saturation binding experiments to kisspeptin receptor
(KISS1R), KP-10 exhibits a KD of 1.0 ± 0.1 nM (52, 53, 56). Additionally, KP-10
presents higher potency than KP-54 (EC50 5.47 ± 0.03 nM), KP-14 (EC50 7.22
±0.07 nM), or KP-13 (EC50 4.62 ± 0.02nM), with an EC50 of 4.13 ± 0.02 nM (52,
53, 56).
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The kisspeptin receptor (KISS1R; formerly known as AXOR12, GPR54 or
hOT7T175) was originally identified as orphan receptor GPR54 by three
independent groups (52, 53, 57). Placental tissue extract was used to purify
peptides to stimulate biological activity of GPR54 and mass spectrometry
revealed these to be KISS1 gene products, kisspeptin (53). KISS1R expression
as determined using reverse transcription polymerase chain reaction was found
in breast, ovary, placenta, pituitary, spinal cord, pancreas, thymus, stomach,
kidney, small intestine, lung, testis, and brain regions (52, 53, 57).
1.3.3 KISS1R Signaling
KISS1R is a G protein-coupled receptor (GPCR) that signals through the
Gq/11-coupled pathway leading to activation of phospholipase C (PLC) (Figure
1.4). PLC signaling in turns causes an increase in inositol 1,4,5-trisphosphate
(IP3) and diacylglycerol formation, an increase in intracellular calcium, and
activation of protein kinase C and extracellular signal-regulated kinase (ERK) 1/2
(52, 53, 57). Additionally, KISS1R has been shown to signal through a G-protein
independent pathway via β-arrestin2, leading to activation of extracellular signalregulated kinase 1/2 (ERK1/2) (58). KISS1R is able to constitutively associate
with β-arrestin1 and β-arrestin2, through residues in the second intracellular loop
and cytoplasmic tail of KISS1R (59). It has been shown that β-arrestin-1 can
inhibit KISS1R signaling whereas β-arrestin-2 stimulates KISS1R signaling to
ERK1/2 (60). With the diverse ability of KISS1R to induce cellular signaling,
understanding the effects of KISS1R signaling is necessary to determine if
KISS1R is a potential therapeutic target in breast cancer.
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Figure 1.4. KISS1R signaling pathways. KISS1R is a Gq/11 coupled receptor
which activation leads to extracellular signal-regulated kinases (ERK1/2)
activation and phospholipase C (PLC) stimulation, calcium mobilization and
protein kinase C (PKC) activity. KISS1R activation can also signal through a G
protein independent pathway via β-arrestin2 mediated ERK1/2 activity.
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1.3.4 Physiological Roles of KISS1R
KISS1R signaling plays a significant role in initiation of puberty as defined
by sexual development, increased bodily growth, and adrenal maturation.
Seminara and colleagues first discovered that a homozygous mutation, L148S, in
KISS1R caused autosomal recessive idiopathic hypogonadotropic hypogonadism
in humans (61). Neuroendocrine research has demonstrated that secretion of
kisspeptin, resulting in KISS1R signaling, conveys control of the reproductive
axis by regulating gonadotropin-releasing hormone (GnRH) release (61-66).
Kisspeptin is secreted in a pulsatile fashion from the arcuate nucleus of the
hypothalamus (67). The kisspeptins in turn act on KISS1R in the median
eminence to cause the release of GnRH into the hypophyseal portal which is
then delivered to and acts on anterior pituitary to cause the release of the
gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
(67). Mice with mutations of the Kiss1r or Kiss1 gene fail to achieve puberty
establishing an essential role for KISS1R signaling during puberty development
(61). Furthermore, Kiss1r-null mice demonstrate a decrease in LH and FSH
serum levels suggesting a crucial role for KISS1R in LH and FSH secretion (6166). Further studies using KISS1-null mice demonstrated that LH and FSH serum
levels could be recovered through subcutaneous injections of kisspeptin-54
which resulted in GnRH release and puberty initiation (66). Finally, studies using
the KISS1R antagonist (P-234) in pre-pubertal rats demonstrated that central
injection of the antagonist could inhibit kisspeptin mediated signaling and delay
puberty (68). Thus, research in kisspeptin signaling has established that KISS1R
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activity is the major regulator of pubertal onset and the major regular of the
hypothalamic-pituitary-gonadal (HPG) axis in several species including humans.
Additionally, kisspeptin/ KISS1R signaling plays an important role in
pregnancy and placentation. High levels of KISS1 and KISS1R gene expression
is found in the human placenta (50, 52, 53, 56, 57). During pregnancy, kisspeptin
and KISS1R expression decreases from first trimester to the third, which
correlates with decreased placental tissue invasion (69, 70). Conversely,
circulating kisspeptin concentrations are increased 1000 fold during the first
trimester and increases to 10,000 fold by the third trimester (69). The varying
expression levels during pregnancy suggest a regulatory role of trophoblastic
invasion during placentation. In vitro studies have demonstrated that kisspeptin10, the kisspeptin splice variant found in the placenta, inhibits migration of
trophoblastic cells and decreases MMP expression which is required from
placental invasion into the uterine walls (71). Furthermore, studies have revealed
an important role for kisspeptin/ KISS1R signaling in maternal artery formation,
required for proper fetal development (71).
1.3.5 KISS1R Signaling In Cancer
The KISS1 gene was originally identified by Lee and colleagues in 1996
as metastasis suppressor gene in melanoma (50). Since this original discovery,
kisspeptin/KISS1R signaling has been further identified to suppress metastasis in
bladder (72), esophageal (73), lung (74), thyroid (75, 76), gastric (77, 78),
ovarian (79-82), and pancreatic (83) cancers. In these cancers, KISS1R
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expression was found to decrease in cancer cells compared to non-malignant
tissue which correlates with poor prognosis in patients. The first study which
examined KISS1 signaling in melanoma found that KISS1 mRNA expression was
found only in non-metastatic melanoma cell lines and absent in metastatic
melanoma cells. Furthermore, when KISS1 was overexpressed, melanoma cell
motility was decreased and metastasis was suppressed in an expressiondependent manner (50). A second study investigated KISS1 expression in
various stages of melanocytic tumors found an inverse correlation of KISS1
expression and melanoma metastases (60). When examination of pancreatic
cancer tissues were performed, a lower expression KISS1 mRNA was observed
in pancreatic cancer as compared to non-malignant tissue (83). Likewise, when
exogenous KISS1 gene was added to pancreatic cancer cells, a reduced
migration of pancreatic cancer cells occurred while having no effect on cellular
proliferation (83). In gastric cancer, KISS1 mRNA expression was reduced in
patients that had lymph node and liver metastases (77). Additionally, the lymph
node and liver metastases demonstrated a reduction of kisspeptin protein
expression as compared to the primary gastric tumor (78). Furthermore, KISS1R
activity in gastric cancer decreases MMP-9 activity, inhibiting invasion, as well as
increasing the tissue inhibitor of metalloprotease (TIMP)-1 (53, 77, 78). In ovarian
carcinoma (79-82), esophageal squamous cell carcinoma (73), and bladder
carcinoma (72), decrease in KISS1 and KISS1R expression was determined to
be a strong prognostic factor for lymph node metastasis.
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1.3.6 KISS1R Signaling in Breast Cancer
In contrast to its metastasis suppressor role in many cancers, studies
indicate that kisspeptin/KISS1R signaling induces a detrimental outcome in
breast cancer. In 2005, the first clinical study focusing on kisspeptin signaling in
breast cancer was carried out. Using quantitative-PCR analysis, Martin and
colleagues measured KISS1 and KISS1R mRNA expression in breast tumor
tissue. An observation of KISS1 mRNA expression was seen to be increased in
breast cancer tissue compared to non-malignant mammary tissue (7).
Furthermore, the breast tumors that had lymph node metastasis demonstrated
an increased KISS1 mRNA levels in comparison to lymph node negative breast
tumors (7). However, KISS1R mRNA expression was not significantly different
between breast tumors and non-malignant tissue or breast tumors that were
lymph node positive or negative for metastases (7). Additionally, overexpression
of KISS1 gene in the human breast cancer MDA-MB-231 cells increased cell
invasiveness and decreased cellular adhesion (7). Finally, this study reported
that KISS1 mRNA expression correlated with poorer prognosis suggesting that
KISS1 gene expression could be used as a prognostic marker in breast cancer
patients (7).
In 2007, Marot and colleagues reported that estrogen status of breast
tumors was correlated to KISS1 mRNA expression. This study observed that
estrogen receptor (ER) α-positive primary breast tumors expressed sevenfold
less KISS1 levels as compared to ERα negative breast tumors (84). Furthermore,
post-menopausal women with ERα positive breast tumors that were treated with

23
the estrogen antagonist, tamoxifen, had higher expression of both KISS1 and
KISS1R mRNA tumor levels (84). This elevation in KISS1 and KISS1R mRNA
tumor levels correlated with reduced relapse-free survival (84). Moreover, KISS1
mRNA expression was found to increase with breast tumor grade (84). To further
evaluate the links between ERα status and KISS1 expression, this study used
ectopic re-expression ERα in the ERα-negative MDA-MB-231 breast cancer cell
line and a corresponding reduction in KISS1 mRNA expression was observed
(84). Likewise, tamoxifen treatment in the ERα-positive MCF7 and T47D breast
cancer cells resulted in an increased expression of KISS1 and KISS1R (84). This
study concluded that KISS1 and KISS1R mRNA levels in breast tumors could be
a marker of tumoral resistance to anti-estrogen treatment. Thus, clinical results
report that kisspeptin/KISS1R signaling may play an important role in breast
cancer progression; however the mechanism by which this occurs remains
elusive.
Presently, a single study has attempted to investigate a role for kisspeptin/
KISS1R signaling in the regulation of breast cancer metastasis. Cho and
colleagues (2011) used a Kiss1r haploinsufficiency mouse model with the
polyoma virus middle T antigen (PyMT) under the control of the mouse mammary
tumor virus (MMTV) promoter (MMTV-PyMT) to investigate the effects of Kiss1r
expression on breast cancer establishment and metastasis. The MMTV-PyMT
mice model enables mammary epithelium transformation into multifocal
mammary adenocarcinoma and lymphatic/lung metastasis (85). This study
demonstrated that loss of Kiss1r expression in Kiss1r heterozygotic PyMT-
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Kiss1r+/− mice attenuated breast tumor initiation, growth, latency, multiplicity and
lung metastasis as compared to the homozygotic PyMT-Kiss1r+/+ mice (86). To
assess the mechanisms by which Kiss1r regulated metastasis, the authors
extracted cells from the primary breast tumors of the PyMT-Kiss1r+/− and PyMTKiss1r+/+ mice for in vitro analysis. Kisspeptin-10 stimulation of Kiss1r in the
extracted cell cultures resulted in small GTPAse RhoA activation through a Gαq
pathway (86). Interestingly, this study also observed that decreased Kiss1r
expression correlated with a significant reduction in VEGF and MMP-9 mRNA
suggesting a possible role for Kiss1r in both angiogenesis and breast cancer
invasion (86). In conclusion, this study suggests kisspeptin/Kiss1r signaling via
RhoA is required for breast cancer metastasis in mouse models.
Studies from our laboratory have provided some insight on the mechanism
by which KISS1R stimulates breast cancer cell migration and invasion, two
processes required for metastasis (87, 88). Our first study found that kisspeptin10 stimulation led to significant increase in MMP-9 secretion and activity in MDAMB-231 breast cancer cells suggesting a mechanism of breast cancer invasion
(88).

Most

interestingly,

we

found

that

kisspeptin-10

induced

EGFR

transactivation in a β-arrestin2 dependent mechanism in ERα-negative breast
cancer cells (88). Furthermore, FRET analysis revealed that KISS1R interacts
directly with EGFR under basal conditions (88). We also found that KISS1R
expression or kisspeptin-10 treatment stimulates EMT of ERα negative MCF10
breast epithelial cells through the increase in N-cadherin and Snail/Slug
expression

resulting

in

increased

cell

invasiveness

(87).

Furthermore,
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overexpression of exogenous KISS1R in ERα-negative SKBR3 breast cancer
cells induced extravasation in vivo using the chick chorioallantoic membrane
(CAM) assay (87). However, kisspeptin-10 treatment failed to induce
invasiveness or EGFR transactivation in the ERα-positive MCF7 and T47D
breast cancer cells suggesting that ERα negatively regulates KISS1R signaling in
breast cancer (87). To confirm this, exogenous ERα was expressed in MDA-MB231 cells which resulted in decreased KISS1R expression and inhibited
kisspepin-10 mediated effects on EGFR transactivation and cell invasion (87).
Finally, the actin cytoskeletal binding protein, IQGAP1, was found to be a novel
binding partner of KISS1R which regulated kisspeptin-10 induced EGFR
transactivation (Figure 1.5) (87). However, whether human KISS1R signaling
regulates breast cancer metastasis is unknown and is a focus of this thesis.
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Figure 1.5. KISS1R signaling pathways in breast cancer. (i) Kisspeptin leads
to KISS1R activation causing transactivation of epidermal growth factor (EGFR)
via β-arrestin2 and IQGAP1 mediated mechanisms. (ii) KISS1R activation leads
to epithelial-mesenchymal transition (EMT) causing a mesenchymal phenotype.
(iii) Likewise, KISS1R activation leads to RhoA anchorage independent growth
and cytoskeletal remodeling. (iv) Estrogen receptor, ERα, down regulates
KISS1R expression in breast cancer cells. Adapted from Cvetkovic et al. 2013
(89).
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1.4.1 β-arrestins
β-arrestin1 and β-arrestin2 are two isoforms of 78% identical amino acid
sequence which have demonstrated a diverse set of roles in cells (90). Studies
have demonstrated abundant expression of β-arrestins in numerous cell types
and are involved in regulating receptor desensitization, internalization and
signaling (91-95). The β-arrestin structure consists of two antiparallel β-sheet
domains with a connecting hinge region and an α-helix amino-terminal tail which
conveys cellular localization (96, 97). Additionally, the hydrophobic core interacts
with phosphorylated residues, important in the interactions of β-arrestins and
GPCRs. Under basal conditions, β-arrestins are phosphorylated on serine 412.
Upon activation, dephosphorylation of serine 412 enables β-arrestin binding to
other proteins such as Src (99).
Originally, β-arrestins were discovered to be a regulator of GPCR
desensitization and internalization. Desensitization and internalization are
mechanisms by which receptor signaling leads to receptor internalization and
directed to either the endosome for receptor recycling or to the lysosome for
destruction (98, 99). During receptor internalization, β-arrestins function in
coordinated effort with GPCR kinases (GRKs) to bind to the phosphorylated
receptor being internalized (100). Desensitization is thought to be an adaptive
response in order to prevent potential detrimental effects from continuous
receptor stimulation (101). By dictating receptor recycling or destruction,
internalization provides control of the duration and intensity of GPCR signaling by
regulating the number of receptors available on the cellular surface for ligand
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binding. Furthermore, the binding of β-arrestin to GPCRs inhibits receptor
coupling to heterotrimeric G proteins, thus limiting G protein mediated signaling.
However, receptor bound β-arrestin can mediate signaling, providing a G protein
independent signaling cascade (102). β-arrestin acts as molecular scaffold by
bringing signaling molecules in proximity to each other; these signaling proteins
include, but are not limited to, Src, ERK1/2, and AKT (97, 103).
1.4.2 β-arrestin and Breast Cancer
β-arrestins are emerging as key regulators of tumorgenesis and metastasis.
In breast cancer, β-arrestins have been shown to regulate breast cancer growth
and proliferation (104). Depletion of β-arrestin1 expression in MCF-7 breast
cancer cells inhibits ERK1/2 and c-JUN activity resulting in decreased cellular
proliferation; thus, implicating a role for β-arrestins in the regulation of breast
cancer cell growth (104). Additionally, β-arrestins regulate breast cancer
migration and invasion (105-107). For instance, protease activated receptor 2
(PAR2) signaling in MDA-MB-231 human breast cancer cells induced cell
migration through a β-arrestin dependent ERK1/2 mechanism (107). Likewise, βarrestin expression is required for LPA1-stimulated migration of MDA-MB-231
cells via small GTPase Ral and Rap (106). One proposed mechanism by which
β-arrestin regulates cancer cell migration involves the interaction of β-arrestin
with the actin filament-severing protein, cofilin. Activation of PAR2 in MDA-MB468 breast cancer cells leads to β-arrestin1 and β-arrestin2 binding to cofilin and
co-localization to the leading edge of migrating cells (108). Furthermore, PAR2
signaling through cofilin is necessary for actin cytoskeleton reorganization and
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chemotaxis (109). Additionally, β-arrestins inhibit LIM kinase, the kinase that
inhibites cofilin activation through serine phosphorylation (108). Moreover, global
proteomics analysis has demonstrated that β-arrestins interact directly with cofilin
and cortactin, two important proteins that regulate invadopodia formation (110).
Beyond primary growth, β-arrestins have also been implicated in the
regulation of breast cancer metastasis. In 2011, Lundgren and colleagues
investigated the expression of β-arrestin1 in clinical breast cancer samples. This
study reported that elevated stromal β-arrestin1 correlated with poor patient
survival (111). Further analysis revealed β-arrestin1 expression to positively
correlate with tumor size, lymph node status, proliferation and distant metastases
(111). Furthermore, this study showed that elevated stromal β-arrestin1 was
linked to increased HIF-1α expression, suggesting a role for β-arrestin1 in
angiogenesis (111). Thus, this study suggests that β-arrestin1 expression is a
negative prognostic marker of patient outcome. A second study by Shenoy and
colleagues (2012), examined β-arrestin1 protein levels in non-malignant and
breast cancer tissues. Infiltrating ductal carcinoma tissue demonstrated elevated
levels of β-arrestin1 in comparison to non-malignant breast tissue suggesting
elevated

β-arrestin1

correlates

with

breast

cancer

progression

(112).

Furthermore, this study used tail vein injection of MDA-MB-231 breast cancer
cells in nude mice to examine the roles of β-arrestin1 and β-arrestin2 in breast
cancer metastasis. Upon depletion of both β-arrestin1 and β-arrestin2, tumor
growth was delayed and mouse survival increased, suggesting a role for βarrestins in breast cancer metastasis (112). Moreover, this study found that β-
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arrestin1 interacts with HIF-1α and controls HIF-1α nuclear trafficking suggesting
a role for β-arrestin1 regulation of nuclear signaling under hypoxic conditions
(112). Likewise, analysis of invasive human breast cancer samples revealed that
increased β-arrestin1 expression correlates with increased levels of VEGF
expression (112). Hence, this study suggests that β-arrestin1 regulates breast
cancer survival and metastatic progression through regulation of pro-angiogenic
factor expression and nuclear signalling.
1.5.1 Rationale
Clinical studies have established a potential role for KISS1R in breast
cancer progression and metastasis (7, 84). Examination of KISS1 and KISS1R
expression in breast cancer has revealed that KISS1 expression is elevated in
human breast cancer tissues and correlates with increased tumor grade and
lymph node metastasis (7). Furthermore, patients with high KISS1 and KISS1R
mRNA expression had shorter relapse-free survival (84). Currently, the only in
vivo study examining the role of KISS1R in breast cancer demonstrated that
decreased mouse Kiss1r expression attenuated breast tumor initiation, growth,
latency and metastasis in MMTV-PyMT/Kiss1r mouse models (86). However, a
role for KISS1R signaling in regulation of human breast cancer metastasis
remains unknown and will be investigated in this study. In our laboratory, our
earlier studies have shown that overexpression of exogenous KISS1R in ERαnegative SKBR3 breast cancer cells increased cellular invasion and induced
extravasation as revealed using the CAM assay (87). Additionally, we have found
that kisspeptin stimulation of ER-negative breast cancer cells leads to increased
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breast cancer cell invasion through kisspeptin-10 EGFR transactivation and
increased MMP-9 activity via a β-arrestin2 dependent mechanism (88). βarrestins have been demonstrated to play a substantial role in breast cancer cell
migration and invasion (88, 105, 106). Furthermore, β-arrestin has been
established to regulate cofilin activity and bind to cortactin, two important proteins
that regulate invadopodia formation. Nevertheless, whether β-arrestins regulate
invadopodia formation and whether KISS1R signaling can promote invadopodia
is unknown and will be investigated here.
1.5.2 Hypothesis
The depletion of KISS1R expression will inhibit human breast cancer cell
metastasis.
1.5.3 Objectives
1) To investigate if KISS1R depletion inhibits human breast cancer
metastasis using an orthotopic xenograft mouse model.
2) To determine the underlying mechanisms of KISS1R signaling in breast
cancer metastasis and invadopodia formation.
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2.1 Materials and Methods
Human Cell Culture. Two breast adenocarcinoma cancer cell lines were used
for this study; the highly metastatic MDA-MB-231 and moderately invasive
Hs578T cell lines (1). The MDA-MB-231 and Hs578T cell lines are estrogen
receptor-α negative and endogenously express epidermal growth factor receptor
and KISS1R (2, 3). Cell lines (all human, all female) were purchased from ATCC
(Manassas, VA) and maintained at 37°C with 5% CO2. Breast cancer cells, MDAMB-231, MDA-MB-231 Scrambled control, MDA-MB-231 KISS1R shRNA #1,
MDA-MB-231 KISS1R shRNA #2, MDA-MB-231 β-arrestin2 shRNA #1, MDAMB-231 β-arrestin2 shRNA #2, Hs578T, Hs578T Scrambled control, Hs578T
KISS1R shRNA #1, and Hs578T KISS1R shRNA #2 are cultured in RPMI 1640
(Invitrogen, Burlington, Ontario, Canada) supplemented with 10% (v/v) fetal
bovine serum (FBS, Sigma).

Stable Transfections and Gene Knockdowns. Gene knockdown of KISS1R, βarrestin 1, β-arrestin 2 in MDA-MB-231 cells and Hs578T cells was achieved as
previously described (2-4). HuSH vectors containing gene specific shRNA and
scrambled controls (OriGene Technologies) were transfected into cells by
electroporation (Gene Pulser Xcell, Bio-Rad), according to the instructions of the
manufacturer (250 V, 950 μF). Heterogeneous populations of stable transfectants
were selected using media containing puromycin (1.5 ng/mL) and expression of
proteins was verified by Western blot analysis.
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Spontaneous Metastasis Assay in NOD/SCID/IL2 receptor γ null Mice. To
assess the role of KISS1R in regulating breast cancer metastasis, we used an
established orthotopic spontaneous metastasis model using NOD/SCID/IL2
receptor γ null immunocompromised mice as described previously (5). MDA-MB231 cells expressing scrambled control or KISS1R shRNA were resuspended in
growth factor-reduced Matrigel (1:1) (1 x 106 cells/mice) and injected into the right
thoracic mammary fat pad of 6 week old female NOD/SCID-IL2Rγ null mice (5
mice/group). Tumor growth was evaluated by caliper measurement bi-weekly, in
three dimensions. At 5 weeks post-injection, mice were sacrificed and primary
tumor and the lungs, liver and mammary fat pads harvested.

Tissues were

collected and fixed in 10% neutral-buffered formalin and embedded in paraffin as
performed by the London Laboratory Services Group at the London Health
Sciences Centre. Each tissue was sectioned 10 times at 4 μm thickness and the
first and final section stained with hematoxylin and eosin for histological analysis
and each adjacent section stained using anti-human Ki67 (1:100, Fisher) to
measure human cell proliferation or with anti-mouse CD-31 (1:100, BD
Bioscience) to measure blood vessel density. Lung metastatic tumor burden was
quantified by measuring the number of metastatic tumors per mm2 and percent of
lung area with metastases as assessed in each hematoxylin and eosin stained
lung section using Aperio ImageScope software. Primary tumor blood vessel
density was determined by counting the total number of blood vessels with CD31 positive staining and dividing by total tumor cross section area as determined
using Aperio ImageScope software. All animal procedures were conducted in
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accordance with the recommendations of the Canadian Council on Animal Care,
under a protocol approved by the University of Western Ontario Council on
Animal Care.

Immunofluorescence

Microscopy.

Immunostaining

was

conducted

as

described previously (2, 3, 6). MDA-MB-231 and Hs578T cells expressing
scrambled control or KISS1R shRNA were washed with Hank's Balanced Salt
Solution, fixed and permeabilized with 4% paraformaldehyde and 0.2% Triton-X
(room temperature, 20min). Phalloidin (1:100, Invitrogen) conjugated to Alexa
Fluor (AF) 555 was incubated for 1 h. Nuclei were stained with 0.01% Hoechst
33258 (Invitrogen). Cells were then washed with Hank's Balanced Salt Solution
(HBSS) and slides mounted using Immuno Mount (Fisher) and #1 glass coverslip
(VWR). Images were acquired using an LSM-510 META laser scanning
microscope (Zeiss, Germany).

Immunoblot Assays. MDA-MB-231 and Hs578T cells stably expressing
scrambled control, KISS1R shRNA, β-arrestin2 shRNA, or β-arrestin1/2 shRNA
were lysed using RIPA buffer (150 mM NaCl, 50 mM Tris pH 8, 5 mM EDTA, 1%
NP40, 0.1% SDS, 10 mM NaF, 0.5% deoxycholate, 10 mM sodium
pyrophosphate, protease inhibitors). Protein (50 μg) was separated by SDSPAGE and protein expression was examined using either: goat anti-KISS1R (N20) sc-48220 (1:1000, Santa Cruz Biotechnology), rabbit anti-Snail/Slug (1:500,
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Santa Cruz), mouse anti-β-catenin (1:1000, BD), rabbit smooth muscle actin
(1:1000, Invitrogen), rabbit anti-laminin V (1:1000 Millipore), anti-β-arrestin1 (1:
300, abcam), anti-β-arrestin2 (1:500, abcam), anti-VEGF (1:200, Santa Cruz),
anti-HIF-α (1:1000 Cell Signaling) and visualized by chemiluminescence.
Densitometric analysis of protein bands was performed using VersaDoc Imaging
System (Bio-Rad). Rabbit β-actin (polyclonal antibody, 1:2000; Sigma)
expression was used to control for equal loading of samples.

Scratch Assays for Cell Motility. MDA-MB-231 and Hs578T cells expressing
shRNA targeting KISS1R or scrambled control were grown to 100% confluence
in a 12-well plate, serum starved in RPMI 1640 media for 24 h, and scratched by
a sterile pipette tip as described previously (2, 3). Cells in fetal bovine serum
supplemented media were allowed to migrate into the scratch for 18 hours and
imaged every 15 minutes using an automated Olympus IX-81 microscope.
Distance travelled was measured and analyzed using ImagePro software.

Cell Migration and Invasion Assays. Transwell chamber migration and
Matrigel-invasion assays were conducted as described (2-4). Transwell filters (8
µm pores) were placed into a 24-well plate containing either serum-free RPMI
1640 media or media supplemented with 10% fetal bovine serum. Cells were
serum-starved for 24 hours. MDA-MB-231 cells and Hs578T (4.0 x 104 cells for
migration assay, 1.0 x 105 cells for invasion assay) expressing scrambled shRNA
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control or KISS1R shRNA were plated in the upper chamber in either serum-free
media or serum-free media supplemented with 100 nM kisspeptin-10 (Phoenix
Pharmaceuticals) and incubated for 20 hours. All experiments were conducted
with kisspeptin-10 concentration of 100 nM based on dose response studies
conducted as described previously (3). For invasion assays, cells were
suspended in 1 in 10 dilution of Matrigel (8.0 mg/mL, BD Biosciences) dissolved
in serum-free RPMI 1640. Cells were then fixed with a 20% acetone: 80%
methanol solution and nuclei stained with 0.1% Hoechst 33258 (Invitrogen). Two
replicates were conducted for each condition and 12 fields (migration assay) or
24 fields (invasion assay) in each replicate were chosen and counted using an
Olympus IX-71 inverted microscope. Results are presented as a ratio of cells that
migrated relative to cells that migrated or invaded in control conditions (cells
seeded in serum-free media and migrating towards media with 10% (v/v) fetal
bovine serum).

Three-Dimensional Invasion Assays. These experiments were conducted as
described previously (2, 3). Matrigel is effective for establishing both malignant
and non-malignant breast cell growth, resembling what is occurring in the in vivo
tumor micro-environment (2, 3, 6, 7). MDA-MB-231 and Hs578T expressing
scrambled control or KISS1R shRNA (2.5 × 104 cells/mL) were seeded in a 1:1
dilution of phenol red-free Matrigel and culture media on Matrigel-coated glassbottomed culture dishes (35 mm, MatTek). Cultures were overlaid with culture
media and maintained for five days. Cell colonies were scored blindly as being
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either stellate or spheroidal. A colony is deemed to be stellate if one or more
projections from the central sphere of a colony of cells are observed. Images
were taken with an Olympus IX-81 microscope (Olympus), using InVivo Analyzer
Suite (Media Cybernetics).

Anchorage-Independent Growth Assay. This assay was conducted as
described (8). One to one dilution of 1.2% agarose (in media) was layered over
3.5 mm wells to form a base. MDA-MB-231 cells (5.0 x 103) expressing
scrambled control or KISS1R shRNA were suspended in 1 to 1 dilution of 0.6 %
agarose in 10% (v/v) fetal bovine serum supplemented with RPMI 1640 medium
and allowed to grow for five weeks to form colonies. Colonies were stained with
crystal violet, imaged with Olympus IX-71 inverted microscope and analyzed
using ImagePro software (Media Cybernetics).

Invadopodia Formation Assay. To assess the ability of cells to form
invadopodia, a gelatin degradation assay was performed using QCM™ Gelatin
Invadopodia Assay kit (Millipore), as described by the manufacturer. Briefly, an 8well chamber slide was coated with poly-L-lysine, followed by glutaraldehyde,
and then fluorescent-gelatin. Following gelatin incubation, each well was
incubated with RPMI 1640 growth media for 30 minutes to quench residual free
aldehydes. Finally, MDA-MB-231 (75,000 cells/cm2) and Hs578T (60,000
cells/cm2) cells were plated in RPMI 1640 growth media and incubated at 37°C
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with 5% CO2 for 24 hours. After incubation, cells were treated with 100 nM
kisspeptin-10 and/or 1 μM P-234 (KISS1R antagonist) for 30 minutes, or left
unstimulated. Following treatment, cells were washed with HBSS, fixed and
permeabilized with 4% paraformaldehyde and 0.2% Triton-X (room temperature,
20min) and blocked with 3% bovine serum albumin. The primary antibody for
cortactin (anti-cortactin antibody, ab33333, abcam) was incubated for 1 hour.
After primary antibody incubation, the following secondary antibodies anti-mouse
DyLight 350 (Thermo/Pierce) and TRITC-phalloidin (2 μg/mL) were incubated
with the cells for 1 hour. Cells were washed with HBSS and slides mounted using
Immuno Mount (Fisher) and #0 coverslip (VWR). Images were acquired using an
LSM-510 META laser scanning microscope (Zeiss, Germany).

Co-localization of Proteins in Invadopodia. To assess the distribution and
localization of endogenous proteins within invadopodia, the gelatin degradation
assays were performed as described above, using fluorescein free gelatin.
Briefly, after 30 minutes of 100 nM kisspeptin-10 stimulation, cells were washed
with HBSS, fixed and permeabilized with 4% paraformaldehyde and 0.2% TritonX (room temperature, 20min) and blocked with 3% BSA. The following primary
antibodies were incubated for 1 hour; anti-KISS1R (N-20) sc-48220 (1:100,
Santa Cruz Biotechnology), anti-cortactin (1:100, ab33333, Abcam), anti-MT1MMP (1:100, Abcam), anti-β-arrestin 2 (1:50, Santa Cruz Biotechnology), antiIQGAP1 (1:50, Santa Cruz Biotechnology), or anti-EGFR (1:50, Abcam).
Subsequently the cells were incubated for 1 hour with the following secondary
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antibodies: anti-rabbit Alexa Fluor (AF) 488 (1:250, Invitrogen), anti-goat AF 555
(1:1000, Invitrogen), anti-mouse DyLight 350 (1:50, Thermo/Pierce) were
incubated with the cells for 1 hour. Cells were washed with HBSS and slides
mounted using Immuno Mount (Fisher) and #0 coverslip (VWR). Images were
acquired using an LSM-510 META laser scanning microscope (Zeiss, Germany).

Cortactin and Cofilin Phosphorylation. MDA-MB-231 cells expressing shRNA
targeting either KISS1R or β-arrestin 2 or scrambled control were grown to 70%
confluence, serum starved for 24 hours and then treated with 100 nM kisspeptin10 for either 5 or 15 minutes. Cells were lysed with RIPA lysis buffer (150 mM
NaCl, 50 mM Tris pH8, 5 mM EDTA, 1% NP40, 0.1% SDS, 10 mM NaF, 0.5%
deoxycholate, 10 mM sodium pyrophosphate, and protease inhibitors) and
proteins (50 μg) were separated by SDS-PAGE. The phosphorylation of cortactin
(anti-cortactin (phospho Y421) antibody ab47768, Abcam) and cofilin (anti-cofilin
(phospho S3 antibody, ab47281, Abcam) was visualized by chemiluminescence.
Total cofilin (cofilin 1 (H-12) sc-32158, Santa Cruz) or total cortactin (anticortactin antibody ab33333, abcam) expression was used to control for equal
loading of samples.

MT1-MMP
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confluence, serum starved for 24 hours, and then treated with 100 nM kisspeptin10 for either 5 or 15 minutes. Cells were lysed with RIPA-modified lysis buffer
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(150 mM NaCl, 50 mM Tris ph8, 5 mM EDTA, 1% NP40, 0.1% SDS, 10 mM NaF,
0.5% deoxycholate, 10 mM sodium pyrophosphate, and protease inhibitors). To
immunoprecipitate MT1-MMP, cell lysates (800 μg) were incubated with antiMT1-MMP (1:200, Abcam) over-night at 4°C. Following antibody incubation,
Dynabeads (Life Technologies) were added to lysates with the antibody for 30
minutes at 4°C. Immunoprecipitated proteins were separated by SDS-PAGE and
MT1-MMP phosphorylation was determined using a mouse monoclonal antiphosphotyrosine antibody (PY-20, Santa Cruz). MT1-MMP phosphorylation was
normalized to total MT1-MMP expression as determined using a rabbit
monoclonal anti-MT1-MMP antibody (1:100, Abcam).

Extravasation In Chick Chorioallantoic Membrane (CAM) Assay. These
experiments were performed as previously described (9-12). On day 12 of
embryonic development, MDA-MB-231 cells expressing shRNA for either
KISS1R, β-arrestin 2, or scrambled control were fluorescently labeled with
CellTracker Green CMFDA (Life Technologies) and injected into a vein within an
intact chorioallantoic membrane. Cells were pre-treated with 10 nM or 100 nM
kisspeptin-10, 1 μM KISS1R antagonist P-234, 1 μM EGFR antagonist AG-1478,
or vehicle (acetonitrile) treatment. Immediately after injection, aluminum foil with
an inner square (1-cm2 region of interest (ROI)) was placed on the surface of the
CAM for macroscopic imaging. The number of cells that arrested within the
capillaries of the ROI were visualized using fluorescence microscopy and
enumerated (t=0). At least 150 cells for each ROI at T=0 was analyzed and
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enumerated. At 24 hours post injection, the ROI was examined again and cells
that extravasated to the stroma were counted allowing percent cellular
extravasation to be determined.

MTT cell viability assays. These assays were conducted using cell proliferation
kit I (MTT) (Roche) as previously described (2). MDA-MB-231 and Hs578T
expressing scrambled control or depleted of KISS1R were seeded in triplicates in
a 96 well plate and grown to 70% confluence. MTT labeling reagent (10 μl) was
added to each well and cells were incubated for 4 h at 37°C and 5.0% CO2.
Following incubation, 100 μl of solubilization reagent was added to each well and
cells were incubated for 24 hours at 37 °C and 5.0% CO 2. Absorbance was then
measured at 550 nm using a SpectraMaxM5MultiMode Microplate Reader
(Molecular Devices) with a background subtraction at 700 nm.

Cell Growth Assay. To determine the rate of cell growth in monolayer culture,
2.0 x 105 MDA-MB-231 and Hs578T cells expressing either scrambled control
shRNA or KISS1R shRNA were plated in 6-well culture plates. At 24 hour
intervals (24, 48, and 72 hours) cell samples were dissociated using trypsin and
the number of cells were determined using a hemocytometer.
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Statistical Analysis
One-way analysis of variance (ANOVA) with a Dunnett’s post-hoc test or twoway ANOVA followed by Bonferroni post-hoc test was performed using
GraphPad Prism 5 (GraphPad Software, Inc.). Differences were considered
statistically significant at p<0.05.
2.2 Results
KISS1R depletion decreases tumor formation and lung metastasis in
xenograft transplantation of human breast cancer cells in mice
The orthotopic xenograft model has been used to effectively study
spontaneous metastasis, allowing tumor cells to undergo all the steps of the
metastatic cascade (5, 13, 14). Hence, to examine the role of KISS1R in breast
cancer metastasis, we used an in vivo orthotopic xenograft spontaneous
metastasis model in NOD/SCID/IL2 receptor γ null mice. For xenograft
transplantation, the human adenocarcinoma breast cancer line MDA-MB-231
was selected due to its highly metastatic characteristics and its endogenous
expression of KISS1R (1). Using two different KISS1R shRNA constructs,
KISS1R expression was depleted in MDA-MB-231 cells, as verified through
western blot (Figure 2.1A) and did not affect cell viability (Figure 2.1B). The three
MDA-MB-231 cell populations of scrambled control, KISS1R shRNA #1, and
KISS1R shRNA #2 were injected into the right mammary fat pad of 6 week mice
(5 mice per cell population). At 5 weeks post-injection, mice were sacrificed and
the primary tumor, lung, liver and brain tissues were removed and examined. We
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observed that upon depletion of KISS1R, primary tumor volume was reduced in
the tumors with cells depleted of KISS1R compared to scrambled control (Figure
2.1C). Furthermore, using hematoxylin and eosin (H&E) staining we observed a
reduction of breast cancer metastasis to lung, where area of metastatic burden
and the number of metastases was reduced in mice injected with cells depleted
of KISS1R compared to control mice (Figure 2.2 A-C). Using anti-human Ki67
antibody, human tumor cell proliferation was visualized within tumors in the lung
sections adjacent to the H&E stained lung sections thus confirming the presence
of human cell metastases (Figure 2.2A). Hence, our data indicates that KISS1R
signaling promotes human breast cancer metastasis in vivo.
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Figure 2.1. KISS1R depletion reduces MDA-MB-231 primary tumor
formation in vivo. (A) Representative Western blots showing expression levels
of endogenous KISS1R MDA-MB-231 in cell populations used for injections.
Western blot analysis with goat polyclonal anti-KISS1R (N-20) antibody.
Quantification of Western blot expression normalized to β-actin (n=4). One-way
ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05. Columns
represent protein expression ± SEM. (B) MDA-MB-231 cells expressing KISS1R
shRNA or scrambled control where cultured in 96 well plate and viability was
determined by MTT assay (n=4). Columns represent absorbance measured at
550nm subtract background reading at 700nm, ± SEM. (C) Primary tumors
formed over 5 weeks formed within the mammary fat pad of NOD/SCID/IL2Rγ
null mice using MDA-MB-231 breast cancer cells expressing scrambled control
shRNA or KISS1R shRNA (106 cells/mouse; 5 mice/cell population). One-way
ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05. Points
represent each mouse tumor volume and bars represent mean volume ± SEM.
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Figure 2.2. KISS1R depletion reduces lung metastatic burden. (A) At 5
weeks post-inject, mice were sacrificed and assessed for metastatic burden in
the lungs. Representative images of lung tissue subjected to either hematoxylin
and eosin or Ki67 staining detected with rabbit monoclonal anti-Ki67 antibody
followed by anti-rabbit HRP conjugate secondary antibody. Lung metastasis
outlined with green. Scale bar, 100 μm. The extent of lung metastasis was
determined by area of lung (B) and number of lung metastases (C) (4
sections/mouse, 5 mice per cell population). One-way ANOVA followed by
Dunnett’s multiple comparison test: *, P < 0.05. Columns represent lung area and
number of metastases ± SEM , respectively.
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KISS1R depletion reduces breast cancer angiogenesis
To determine the mechanism by which KISS1R depletion reduced breast
cancer metastasis, we investigated the role of KISS1R in the promotion of
angiogenesis. Using the primary tumor sections from the orthotopic xenograft
experiments, we stained for blood vessel formation using CD31, a marker for
endothelial cells (Figure 2.3A). In the primary tumors depleted of KISS1R, we
observed a reduction in the blood vessel density in tumors depleted of KISS1R
(Figure 2.3B). Vascular endothelial growth factor (VEGF) and transcription factor
hypoxia-inducible factor-1(HIF-1α) are two proteins whose expression has been
demonstrated to increase with breast cancer progression, leading to the
promotion of angiogenesis (15, 16). Hence, we assessed whether KISS1R
regulated the expression of VEGF and HIF-1α in MDA-MB-231 cells. We
observed that a reduction in KISS1R expression in MDA-MB-231 cells was
associated with a reduction in both VEGF and HIF-1α (Figure 2.4). Hence, our
results implicate a possible mechanism by which KISS1R promotes breast
cancer angiogenesis.
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Figure 2.3. Depletion of KISS1R reduces breast cancer angiogenesis in
vivo. (A) Representative images of blood vessels stained with CD31 mouse in
primary tumors subjected to hematoxylin counter stain. Mouse CD31 was
detected with rat monoclonal anti-mouse CD31 antibody followed by anti-rat HRP
conjugate secondary antibody. Scale bar, 100 μm. (B) Number blood vessels in
primary tumors formed within the mammary fat pad of NOD/SCID/IL2rγ mice
injected with MDA-MB-231 breast cancer cells expressing scrambled control
shRNA or KISS1R shRNA (5 mice/cell population). One-way ANOVA followed by
Dunnett’s multiple comparison test: *, P < 0.05. Columns represent number of
blood vessels ± SEM.
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Figure 2.4. KISS1R expression regulates the pro-angiogenic factors in
breast cancer cells. Representative Western blots showing expression levels of
endogenous VEGF and HIF-1α in MDA-MB-231 cells depleted of KISS1R.
Western blot analysis with a rabbit polyclonal anti-HIF-1α antibody and rabbit
polyclonal anti-VEGF antibody (n=4). Quantification of Western blot expression
normalized to β-Actin. One-way ANOVA followed by Dunnett’s multiple
comparison test: *, P < 0.05. Columns represent protein expression ± SEM.
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KISS1R depletion reduces the mesenchymal phenotype of human breast
cancer cell lines MDA-MB-231 and Hs578T
To better understand the mechanism by which KISS1R signaling regulates
metastasis, we investigated the effect of KISS1R depletion on breast cancer
mesenchymal phenotype. Hence we depleted KISS1R in two invasive human
adenocarcinoma breast cancer cell lines, MDA-MB-231 and Hs578T. Expression
of two different KISS1R shRNA constructs in Hs578T cells depleted KISS1R
expression as verified through western blot (Figure 2.5A) and did not affect cell
viability (Figure 2.5B). Upon depletion of KISS1R we observed a reduction in
mesenchymal morphology as characterized by a loss of long, spindle shaped
morphology of invasive breast cancers cells (Figure 2.5C).

Furthermore, a

reduction of KISS1R expression decreased actin stress fiber formation in breast
cancer cells (Figure 2.6). We have previously reported that overexpression of
KISS1R stimulates epithelial-to-mesenchymal transition in the non-malignant
human MCF10A mammary epithelial cells and the human breast cancer SKBR3
cells (2). Hence, we assessed whether depletion of KISS1R regulated the
expression of mesenchymal markers smooth muscle actin, β-catenin, and
Snail/Slug. We found that the depletion of KISS1R resulted in the loss of
expression of these markers in MDA-MB-231 and Hs578T breast cancer cells in
comparison to scrambled control (Figure 2.7, 2.8). Hence, our results reveal that
KISS1R expression regulates the mesenchymal phenotype of breast cancer
cells.
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Figure 2.5. Depletion of KISS1R expression reduces the mesenchymal
phenotype of MDA-MB-231 and Hs578T breast cancer cells.
(A)
Representative Western blots showing expression levels of endogenous KISS1R
in Hs578T breast cancer cells expressing KISS1R shRNA or scrambled control.
Western blot analysis with goat polyclonal anti-KISS1R (N-20) antibody.
Quantification of Western blot expression normalized to β-actin (n=3). One-way
ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05. Columns
represent protein expression ± SEM. (B) Hs578T cells expressing KISS1R
shRNA or scrambled control where cultured in 96 well plate and viability was
determined by MTT assay (n=3-4). Columns represent absorbance measured at
550nm subtract background reading at 700nm, ± SEM. (C) Representative DIC
images of MDA-MB-231 and Hs578T breast cancer cells expressing scrambled
control shRNA or KISS1R shRNA (n=3). 40x. Scale bar, 100 μm.
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Figure 2.6. Reduction in KISS1R expression reduces stress fiber formation
in MDA-MB-231 and Hs578T cells. F-actin stained with phalloidin -Alexa Fluor
555 (red) and nuclei stained using Hoechst 33258 (blue) and visualized by
confocal microscopy. Images representative of three independent experiments.
Scale bar, 20 μm.
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Figure 2.7. Decreased expression of KISS1R reduces mesenchymal
markers in MDA-MB-231 cells.
Representative Western blots showing
expression levels of KISS1R and mesenchymal markers β-catenin (n=4),
Snail/Slug (n=3) and smooth muscle actin (SMA) (n=3) in MDA-MB-231 breast
cancer cells expressing scrambled shRNA or KISS1R shRNA. Western blot
analysis performed with mouse monoclonal anti-β-catenin, rabbit polyclonal antiSnail/Slug, and mouse monoclonal anti-smooth muscle actin. Quantification of
Western blot expression normalized to β-actin. One-way ANOVA followed by
Dunnett’s multiple comparison test: *, P < 0.05. Columns represent protein
expression ± SEM.
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Figure 2.8. Decreased expression of KISS1R reduces mesenchymal
markers in Hs578T cells. Representative Western blots showing expression
levels of KISS1R and mesenchymal markers β-catenin (n=3) and Snail/Slug
(n=3) in Hs578T breast cancer cells expressing scrambled shRNA or KISS1R
shRNA. Western blot analysis performed with mouse monoclonal anti-β-catenin
and rabbit polyclonal anti-Snail/Slug. Quantification of Western blot expression
normalized to β-actin. One-way ANOVA followed by Dunnett’s multiple
comparison test: *, P < 0.05. Columns represent protein expression ± SEM.
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KISS1R depletion reduces breast cancer cell migration.
The ability of cancer cells to metastasize is dependent on two important
cellular functions, the cell’s capacity to invade or degrade the surrounding tissue
as well as the cell’s ability to migrate through the space, away from the primary
tumor (17-19). To assess a role of KISS1R in promoting migration, we first used
scratch migration assays. We found that reduction of KISS1R expression
decreased the distance migrated in comparison to cells expressing scrambled
control (Figure 2.9). We have previously reported that kisspeptin-10 increases
migration and invasion at maximal response observed using 100 nM
concentration, thus all of our following experiments were conducted using 100
nM kisspeptin-10 (2, 3, 12, 20, 21). Migration was also measured using the
transwell chamber migration assays. MDA-MB-231 or Hs578T cells expressing
scrambled control or KISS1R shRNA were seeded in serum-free media or serum
free media containing 100 nM kisspeptin-10 and allowed to migrate for 20 hours.
The depletion of KISS1R reduced basal migration as well as kisspeptin-10
stimulated migration (Figure 2.10). Moreover, we saw no differences in cell
proliferation suggesting that the observed differences in scratch closure and
transwell migration assays are due to changes in cell migration and not increase
in cellular proliferation (Figure 2.11). Hence, these results suggest that KISS1R
signaling regulates breast cancer cell migration.
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Figure 2.9. Depletion of KISS1R inhibits breast cancer scratch wound
closure. Decreased expression of KISS1R reduces the distance closed by (A)
MDA-MB-231 and (B) Hs578T cells in a scratch assay over an 18 hour and 15
hour period, respectively. Two-way ANOVA followed by Bonferroni post hoc test:
a, P < 0.05 for KISS1R shRNA construct #1 vs. scrambled control; b, P <0.05
KISS1R shRNA construct #2 vs. scrambled control. Scale bar, 100 μm.
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Figure 2.10. Depletion of KISS1R expression inhibits MDA-MB-231 and
Hs578T cell transwell chamber migration. Depletion of KISS1R in (A) MDAMB-231 and (B) Hs578T cells decreases the number of cells migrated towards
10% fetal bovine serum (FBS) under basal conditions and inhibits kisspeptin-10
induced cell migration (n=3-6). Two-way ANOVA followed by Bonferroni post hoc
test: a, P < 0.05 for significant difference vs. scrambled control non-stimulated; b,
P < 0.05 for significant difference vs. scrambled control 100 nM kisspeptin-10.
Columns represent cells migrated to lower chamber ± SEM.

68

Figure 2.11. KISS1R depletion does not affect cell proliferation rate over a
72 hour period. (A) MDA-MB-231 or (B) Hs578T cells expressing KISS1R
shRNA or scrambled control where cultured for 72 hours and counted at 24 hour
intervals (n=3).
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Decreased KISS1R expression diminishes breast cancer cell invasion.
Both malignant and non-malignant breast cell lines can be cultured in
Matrigel, a reconstituted extracellular matrix that mimics the in vivo tumor microenvironment (2-4, 7). MDA-MB-231 and Hs578T breast cancer cells cultured in
the three-dimension (3D) Matrigel assay formed less invasive (stellate) colonies
when depleted of KISS1R in comparison to cells expressing scrambled control
(Figure 2.12, 2.13). Furthermore, we observed that KISS1R depletion reduced
basal and kisspeptin-10 induced breast cancer cell invasion using transwell
membrane invasion assays (Figure 2.14). Overall, these findings suggest that
KISS1R signaling promotes the invasiveness of breast cancer cells and that this
may be a mechanism by which depletion of KISS1R inhibited metastasis in vivo.
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Figure 2.12. Decreased KISS1R expression inhibits MDA-MB-231 breast
cancer cell invasion in three-dimensional Matrigel assay. MDA-MB-231 cells
expressing KISS1R shRNA suspended in Matrigel for 5 days display reduced
growth of invasive stellate structures relative to cells expressing scrambled
control (n=3-5). Scale bar, 100 μm. Two-way ANOVA followed by Bonferroni
post hoc test: a, P < 0.05 for KISS1R shRNA construct #1 vs. scrambled control;
b, P <0.05 KISS1R shRNA construct #2 vs. scrambled control.
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Figure 2.13. Decreased KISS1R expression inhibits Hs578T breast cancer
cell invasion in three-dimensional Matrigel assay. Hs578T cells expressing
KISS1R shRNA suspended in Matrigel for 5 days display reduced growth of
invasive stellate structures relative to cells expressing scrambled control (n=3).
Scale bar, 100 μm. Two-way ANOVA followed by Bonferroni post hoc test: a, P
< 0.05 for KISS1R shRNA construct #1 vs. scrambled control; b, P <0.05 KISS1R
shRNA construct #2 vs. scrambled control.
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Figure 2.14. Depletion of KISS1R expression inhibits breast cancer cell
invasion in Matrigel transwell chamber invasion assay. Decreased KISS1R
expression reduces (A) MDA-MB-231 and (B) Hs578T cell invasion towards 10%
fetal bovine serum (FBS) at basal conditions and inhibits kisspeptin-10 induced
invasion (n=3-5). Two-way ANOVA followed by Bonferroni post hoc test: a, P <
0.05 for significant difference vs. scrambled control non-stimulated; b, P < 0.05
for significant difference vs. scrambled control 100 nM kisspetin-10. Columns
represent cells invaded to lower chamber ± SEM
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KISS1R depletion decreases colony formation by breast cancer cells
To establish a role for KISS1R in breast cancer tumorigenicity, we
conducted the anchorage independent assays. MDA-MB-231 cells depleted of
KISS1R or expressing the scrambled control were cultured in agar and then the
numbers of colonies that formed were counted. Compared to the scrambled
control, cells depleted of KISS1R showed a dramatic decrease in colony
formation (Figure 2.15). Thus, our data suggest that KISS1R expression
regulates the ability of metastatic breast cancer cells to grow in an anchorageindependent environment suggesting a mechanism by which KISS1R signaling
may influence primary tumor growth.
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Figure 2.15. KISS1R depletion in MDA-MB-231 cells reduces anchorage
independent growth. (A) MDA-MB-231 expressing scrambled control shRNA or
KISS1R shRNA was grown in agarose for 6 weeks (n=4-5). Reduction in KISS1R
decreased the number of colonies greater than 50 μm in diameter as compared
to cells expressing scrambled control. One-way ANOVA followed by Dunnett’s
multiple comparison test: *, P < 0.05. Columns represent colonies greater than
50 μm in diameter, ± SEM. (B) Representative pictures of MDA-MB-231 cellular
colonies at 6 weeks. Scale bar, 200 μm.
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Kisspeptin Signaling Stimulates Invadopodia Formation
Our data thus far indicates that KISS1R signaling plays a role in promoting
breast cancer cell invasion. To evaluate the mechanism by which KISS1R
promotes cell invasion, we used a gelatin degradation assay to assess the ability
of kisspeptin-10 to stimulate invadopodia. Invadopodia formed by cells degrade
the gelatin leaving darkened areas or “holes” in the areas depleted of gelatin (22,
23). The ability for invadopodia to form and degrade the gelatin is dependent on
cortactin and F-actin; these two proteins display a punctate pattern and colocalize at points of degradation (23, 24). Hence, invadopodia formation was
determined by measuring the number of cells forming F-actin-cortactin colocalization punctate pattern with associated underlying gelatin degradation
(Figure 2.16A). MDA-MB-231 or Hs578T cells were plated on gelatin for 24 hours
and then stimulated with 100 nM kisspeptin-10 for 30 minutes. Upon kisspeptin10 stimulation, the number of cells with invadopodia formation increased
significantly compared to basal levels (Figure 2.16B). Furthermore, we observed
that pre-treatment with the KISS1R antagonist, P-234 (1 μM), inhibited
kisspeptin-10 induced invadopodia formation (Figure 2.16B). Overall, our data
reveals for the first time that KISS1R stimulates invadopodia formation in breast
cancer cells.
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Figure 2.16. Activation of KISS1R promotes invadopodia formation. (A)
Representative pictures of invadopodia formation via actin (phalloidin, red) and
cortactin (blue) organization promoting gelatin degradation. Cortactin
immunostaining detected using mouse monoclonal anti-cortactin antibody,
followed by DyLight 350 secondary antibody. Images are representative of three
independent experiments. Scale bar, 10 μm. (B) Treatment of MDA-MB-231 or
Hs578T breast cancer cells with 100 nM kisspeptin-10 causes an increase in the
number if cells with invadopodia formation. Pre-treatment with the KISS1R
antagonist, P-234, inhibits kisspeptin-10 induced invadopodia formation (n=3).
One-way ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05.
Columns represent percent of cells with invadopodia ± SEM.
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Kisspeptin stimulation increases cortactin and cofilin activity
Invadopodia formation is dependent on the activity of two proteins,
cortactin and cofilin (23, 25). The activities of both of these proteins are
dependent on their phosphorylation status, where dephosphorylation can be
associated with increased activity and maturation of invadopodia (23, 26-29). To
evaluate if KISS1R regulates the activity of cofilin and cortactin we stimulated
MDA-MB-231 breast cancer cells with kisspeptin-10 (100 nM) for 5 and 15
minutes and evaluated changes in phosphorylation of either cortactin (Y421) or
cofilin (S3). Upon stimulation of the MDA-MB-231 cells with kisspeptin-10, we
saw
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dephosphorylation for cofilin at 15 minutes (Figure 2.17). These results
demonstrate that kisspeptin-10 treatment of breast cancer cells increases the
activity of the proteins involved in invadopodia formation. Furthermore, we found
that upon depletion of KISS1R, kisspeptin-10 mediated dephosphorylation of
cortactin and cofilin was inhibited at both time points (Figure 2.18). Our results
thus indicate that kisspeptin-10 signaling via KISS1R stimulates cortactin and
cofilin activity necessary to promote invadopodia formation in breast cancer cells.
Furthermore, we observed that KISS1R is co-localized in invadopodia with
cortactin, IQGAP1, EGFR, and MT1-MMP, proteins essential for the formation
and invasive capacity of invadopodia (22, 30) (Figure 2.23).
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Figure 2.17. KISS1R signaling promotes cortactin and cofilin activity.
Treatment of MDA-MB-231 breast cancer cells with 100 nM kisspeptin-10 caused
a decrease in the phosphorylation of cofilin and cortactin. Western blot analysis
with a rabbit polyclonal anti-phospho cortactin (Y421) antibody, rabbit polyclonal
anti-phospho cofilin (S3), mouse monoclonal anti-cortactin, and mouse
monoclonal anti-cofilin. Phosphorylation levels are normalized to total cofilin or
total cortactin (n=5). One-way ANOVA followed by Dunnett’s multiple comparison
test: *, P<0.05. Columns represent protein phosphorylation ± SEM.
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Figure 2.18. Depletion of KISS1R expression inhibits kisspeptin-10 induced
decreases in cortactin and cofilin activity. Treatment with kisspeptin-10 100
nM was unable to decrease cofilin and cortactin phosphorylation of MDA-MB-231
breast cancer cells depleted of KISS1R. Phosphorylation levels are normalized to
total cofilin or total cortactin (n=3-5). One-way ANOVA followed by Bonferroni
post hoc test: a, P < 0.05 for significant difference vs. scrambled control
kisspeptin-10 0 minutes; b, P < 0.05 for significant difference vs. scrambled
control kisspeptin-10 5 minutes; c, P < 0.05 significant difference vs. scrambled
control kisspeptin-10 15 minutes. Columns represent protein phosphorylation ±
SEM.
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Figure 2.19. KISS1R co-localizes with endogenous cortactin, EGFR, MT1MMP, and IQGAP1 in invadopodia. Co-localization of endogenous KISS1R
with (A) MT1-MMP and cortactin or (B) MT1-MMP and EGFR or (C) MT1-MMP
and IQGAP1or (D) IQGAP1 and cortactin. Images are representative of three
independent experiments. Scale bar, 10 μm. KISS1R immunofluorescence
detected using goat polyclonal KISS1R (N-20) antibody followed by an anti-goat
Alexa Fluor 555 (red); EGFR detected using mouse monoclonal anti-EGFR
antibody followed by anti-mouse DyLight 350 (blue); MT1-MMP detected using
rabbit monoclonal anti-MT1-MMP antibody followed by anti-rabbit Alexa Fluor
488 (green); Cortactin detected using mouse monoclonal anti-cortactin antibody
followed by anti-mouse DyLight 350 (blue); IQGAP1 detected using either
mouse or rabbit monoclonal anti-IQGAP1 antibody followed by anti-mouse
DyLight 350 (blue) or anti-rabbit Alexa Fluor 488 (green).

81
Kisspeptin-10 induces MT1-MMP Tyrosine Phosphorylation.
The activation of MT1-MMP by tyrosine phosphorylation of Tyr 573 by Src
kinase has been recognized to increase cellular migration and matrixdegradation in 3D matrices (31, 32). Furthermore, an in vivo study using a
subcutaneous tumor injection into the flanks of mice observed that Tyrosine 573
mutation inhibiting tyrosine phosphorylation resulted in decreased tumor
progression, increased tumor necrosis, and increased survival suggesting a
direct role for MT1-MMP tyrosine phosphorylation in cancer progression (33).
Thus, to evaluate if KISS1R signaling could activate MT1-MMP, we stimulated
MDA-MB-231 cells with kisspeptin-10 100 nM for 5 and 15 minutes and observed
for changes in MT1-MMP tyrosine phosphorylation. Using immunoprecipitation of
MT1-MMP and an anti-tyrosine-phosphorylation antibody, we observed increase
in tyrosine phosphorylation at both 5 and 15 minutes of kisspeptin-10 stimulation,
with a significant increase at 5 minutes (Figure 2.20). Thus, this result suggests
KISS1R stimulation may cause an increased MT1-MMP activity which is
important in invadopodia invasive function.

82

Figure 2.20. Kisspeptin stimulation increases MT1-MMP tyrosine
phosphorylation. Treatment of MDA-MB-231 breast cancer cells with 100 nM
kisspeptin-10 causes an increase in MT1-MMP tyrosine phosphorylation.
Western blot analysis with a mouse monoclonal anti-phosphotyrosine antibody
and rabbit monoclonal anti-MT1-MMP. Phosphorylation levels are normalized to
total MT1-MMP (n=3). One-way ANOVA followed by Dunnett’s multiple
comparison test: *, P<0.05. Columns represent protein phosphorylation ± SEM.
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β-arrestin2 regulates kisspeptin mediated invadopodia formation
KISS1R promotes invasion by stimulating the secretion and activity of
MMP-9 via a β-arrestin2 dependent mechanism (3) Likewise, β-arrestin2 has
shown to be a direct binding partner for the invadopodia precursors cofilin,
cortactin, and IQGAP1 (6, 34, 35). Hence, we determined whether β-arrestin2 is
also localized to invadopodia. Indeed, we observed that β-arrestin2 is localized to
invadopodia and co-localizes with MT1-MMP, cortactin and KISS1R suggesting a
possible role for β-arrestin2 in regulating KISS1R mediated invadopodia
formation (Figure 2.21). Therefore, to investigate a role of β-arrestin2 in
invadopodia formation, we depleted β-arrestin2 in MDA-MB-231 cells as verified
through western blot (Figure 2.22A). Using the gelatin degradation assay, we
observed a reduction of invadopodia formation in cells depleted of β-arrestin2
(Figure 2.22B). Furthermore, β-arrestin2 depletion inhibited the ability of
kisspeptin-10 100 nM to increase invadopodia formation (Figure 2.22B). Finally,
we investigated if β-arrestin2 regulated kisspeptin-10 mediated decrease in
phosphorylation of both cortactin and cofilin. We found that upon depletion of βarrestin2, kisspeptin-10 mediated dephosphorylation of cortactin and cofilin was
inhibited (Figure 2.23).
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Figure 2.21. β-arrestin2 co-localizes with cortactin, MT1-MMP, and KISS1R
in invadopodia. Co-localization of endogenous β-arrestin2 with (A) MT1-MMP
and cortactin or (B) KISS1R and MT1-MMP. Images are representative of three
independent experiments. Scale bar, 10 μm. β-arrestin2 detected using goat
polyclonal anti-β-arrestin2 followed by anti-goat Alexa Fluor 555 (red); MT1-MMP
detected using rabbit monoclonal anti-MT1-MMP antibody followed by anti-rabbit
Alexa Fluor 488 (green); cortactin detected using a mouse monoclonal anticortactin antibody followed by anti-mouse DyLight 350 (blue); KISS1R
immunofluorescence detected using goat polyclonal KISS1R (N-20) antibody
followed by an anti-goat Alexa Fluor 555 (red).
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Figure 2.22. β-arrestin2 depletion inhibits invadopodia formation. (A)
Representative Western blots showing expression levels of β-arrestin2 in MDAMB-231 breast cancer cells expressing β-arrestin2 shRNA or scrambled control.
Western blot analysis with mouse monoclonal anti-β-arrestin2 antibody.
Quantification of Western blot expression normalized to β-actin (n=3). One-way
ANOVA followed by Dunnett’s multiple comparison test: *, P < 0.05. Columns
represent protein expression ± SEM. (B) Depletion of β-arrestin2 decreases
invadopodia formation at basal conditions and inhibits kisspeptin mediated
invasion. Two-way ANOVA followed by Bonferroni post hoc test: a, P < 0.05 for
significant difference vs. scrambled control kisspeptin-10 0 minutes; b, P < 0.05
for significant difference vs. scrambled control kisspeptin-10 5 minutes; c, P <
0.05 significant difference vs. scrambled control kisspeptin-10 15 minutes.
Columns represent protein phosphorylation ± SEM.
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Figure 2.23. β-arrestin2 regulates kisspeptin-10 induced cortactin and
cofilin activity. β-arrestin2 depletion in MDA-MB-231 breast cancer cells inhibits
kisspeptin-10 100 nM induced cofilin and cortactin dephosphorylation.
Phosphorylation levels are normalized to total cofilin or total cortactin (n=3-5).
Two-way ANOVA followed by Bonferroni post hoc test: a, P < 0.05 for significant
difference vs. scrambled control kisspeptin-10 0 minutes; b, P < 0.05 for
significant difference vs. scrambled control kisspeptin-10 5 minutes; c, P < 0.05
significant difference vs. scrambled control kisspeptin-10 15 minutes. Columns
represent protein phosphorylation ± SEM.
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KISS1R signaling promotes breast cancer extravasation in vivo.
The ability of cells to form invadopodia has been linked to the capability of
cancer cells to intravasate and extravasate during metastasis (18, 36).
Extravasation is the event of metastasis where cancer cells leave the blood
vasculature and enter the surrounding tissue. The chick chorioallantoic
membrane (CAM) assay is a well-established model to measure cell
extravasation by cancer cells in vivo (18, 36). MDA-MB-231 cells were injected
into the chorioallantoic membrane of 12 day old chick embryos. A significant
increase in cell extravasation was observed with 10 nM or 100 nM kisspeptin-10
treatments (Figure 2.24). Pre-treatment of the cells with 1 μM P-234 KISS1R
antagonist or 1 μM AG-1478 EGFR antagonist or combination of both inhibitors
significantly blocked extravasation (Figure 2.24). Also, KISS1R depletion
significantly reduced MDA-MB-231 cell extravasation in comparison scrambled
controls treated with vehicle or kisspeptin-10 10 nM (Figure 2.29). Overall, these
results suggest that activation of KISS1R stimulates breast cancer cell
extravasation, which can be blocked by inhibiting KISSR and/or EGFR activity.
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Figure 2.24. KISS1R antagonism attenuates MDA-MB-231 breast cancer cell
extravasation in the chick chorioallantoic membrane (CAM) assay.
Kisspeptin-10 (10 nM) significantly increased the number of MDA-MB-231 cells
extravasating compared to vehicle control (n=14-18). Pre-treatment of cells with
KISS1R antagonist P-234, and/or EGFR antagonist AG 1478 significantly
reduced the percentage of cells extravasated compared to vehicle control or 10
nM kisspeptin-10 treatment (n=3-6). One-way ANOVA followed by Bonferroni
post hoc test: a, P<0.05 compared to vehicle treated scrambled control; b,
P<0.05 compared to 10 nM kisspetin-10 treated scrambled control. Columns
represent % cell extravasation ± SEM.
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Figure 2.25. Depletion of KISS1R decreases breast cancer cell
extravasation. Decreased KISS1R expression in MDA-MB-231 cells inhibits cell
extravasation compared to scrambled control vehicle or 10 nM kisspeptin-10
treatments (control groups: n=14-18; KISS1R shRNA groups: n=5-6). Two-way
ANOVA followed by Bonferroni post hoc test: a, P<0.05 compared to vehicle
treated scrambled control; b, P<0.05 compared to 10 nM kisspeptin-10 treated
scrambled control. Columns represent % cell extravasation ± SEM.
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β-arrestin2 regulates KISS1R induced extravasation of breast cancer cells.
Thus far our data supports the premise that β-arrestin2 regulates
kisspeptin-10 induced invadopodia formation. Hence, we sought to investigate
whether KISS1R stimulates breast cancer extravasation via β-arrestin2. MDAMB-231 cells depleted of β-arrestin2 were used in the CAM assay. Depletion of
β-arrestin2 decreased basal and kisspeptin-10 induced extravasation as
compared to scrambled controls (Figure 2.26). These results demonstrate that βarrestin2 not only regulates invadopodia formation by also breast cell
extravasation in vivo.
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Figure 2.26. β-arrestin depletion attenuates breast cancer cell
extravasation. Depletion of β-arrestin2 in MDA-MB-231 cells significantly
reduced percent cell extravasation in comparison scrambled control vehicle and
10 nM kisspeptin-10 treatments (control groups: n=14-18, β-arrestin shRNA
groups: n=5-6). Two-way ANOVA followed by Bonferroni post hoc test: a, P<0.05
compared to vehicle treated scrambled control; b, P<0.05 compared to 10nM
kisspetin-10 treated scrambled control. Columns represent % cell extravasation
± SEM.
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3.1 Summary of Novel Findings and Conclusions
Objective #1: To investigate if KISS1R depletion inhibits human breast cancer
metastasis using an orthotopic xenograft mouse model.
Orthotopic xenograft tumors established with MDA-MB-231 human breast
cancer cells depleted of KISS1R in NOD/SCID/IL2Rγ null mice resulted in
decreased size and number of lung metastases. Hence, our results indicate that
KISS1R signaling promotes human breast cancer metastasis in vivo.
Objective #2: To determine the underlying mechanisms of KISS1R signaling in
breast cancer metastasis and invadopodia formation.
Depletion of KISS1R expression resulted in decreased orthotopic tumor
blood vessel density and decreased expression of breast cancer cell proangiogenic factors. Furthermore, KISS1R depletion resulted in a reduction in
breast cancer cell mesenchymal phenotype and decreased breast cancer cell
migration and invasion, two important cellular characteristics involved in cancer
metastasis. Additionally, we found that KISS1R signals via β-arrestin2 to regulate
invadopodia formation and extravasation. Thus, our results reveal a mechanism
by which KISS1R signaling promotes breast cancer metastases by means of
angiogenesis, migration and invasion, invadopodia formation, and extravasation.
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3.2 Contributions of Research to Current State of Knowledge
The importance of GPCR signaling in physiological and pathological
events is well established (1, 2). GPCR signaling involves a complex cascade of
G protein dependent and G protein-independent signaling pathways. The
transactivation of EGFR by GPCRs has been demonstrated in breast, lung,
ovarian, colon and prostate cancers (3). Similarly, EGFR overexpression in
several cancers leads to increased cell survival, proliferation, and invasion (4, 5).
Tyrosine kinase inhibitors targeting EGFR activity have been developed.
However, clinical results show EGFR inhibition has limited anti-metastatic affects
due to the acquisition of drug resistance (6). Studies from our laboratory have
revealed that KISS1R transactivates EGFR, through a β-arrestin2 and IQGAP1
mechanism, leading to breast cancer cell invasion (7, 8). Thus, targeting both
KISS1R and EGFR together may provide an effective therapeutic strategy in the
prevention of breast cancer progression and metastasis. Likewise in triplenegative breast cancer, an effective therapeutic target remains elusive resulting
in poor patient survival (9, 10). The identification of KISS1R as novel therapeutic
target may provide a solution for those suffering from triple-negative cancer.
Role of KISS1R Signaling in Breast Tumor Formation and Metastasis
In agreement with our findings, Cho and colleagues (2011) showed that
the loss of KISS1R in heterozygotic PyMT-KISS1R+/− mice resulted in attenuated
breast tumor initiation, growth, latency, multiplicity and lung metastasis as
compared to the homozygotic PyMT-KISS1R+/+ mice (11). This study used a
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MMTV-PyMT virus mediated initiation of breast cancer in mice mammary cells.
Hence, whether KISS1R signaling in human breast cancer promotes metastasis
remains unknown. For our study, we used a pre-clinical orthotopic xenograft
mouse model to determine the role of KISS1R signaling in human breast cancer
metastasis. The orthotopic xenograft mouse model has been shown to accurately
recapitulate breast cancer gene expression profiles as seen in patient primary
breast tumors providing an accurate model to assess the role of KISS1R in
human breast cancer metastasis (12). Thus, our results support and augment the
findings from the Cho et al. (2011) study by demonstrating for the first time that
depletion in KISS1R expression in the human breast cancer cells decreases the
number and area of lung metastases in vivo.
In our orthotopic xenograft mouse model we observed that KISS1R
depletion significantly reduced primary tumor volume, thus possibly contributing
to the amount of lung metastases observed. The capacity of tumors to stimulate
angiogenesis has been shown to control tumor growth and volume (13). We saw
that KISS1R depletion decreased blood vessel formation in the primary tumors
established in vivo. Furthermore, depletion of KISS1R expression in MDA-MB231 cells decreased the pro-angiogenic factors VEGF and HIF-1α. Cho et al.
(2011) also reported that mouse breast cancer cells with reduction in KISS1R
expression correlated with significant reduction in VEGF mRNA expression (11).
A second possible mechanism by which the in vivo tumor volumes differed is
through KISS1R regulation of cancer cellular proliferation. Cho et al. (2011)
demonstrated that breast cancer cells cultured from KISS1R heterozygotic
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PyMT-KISS1R+/− mice had a significant reduction in cellular proliferation
compared to cancer cells cultured from KISS1R homozygotic PyMT-KISS1R+/+
mice (11). Our study did not find a difference in cell proliferation in breast cancer
cells depleted of KISS1R over a relatively short 72 hour period. However, using
an anchorage-independent growth assay, we observed for the first time that
depletion of KISS1R expression reduced colony formation over a 6 week period.
The anchorage-independent growth assay is a well-established model to
measure cell proliferation independent of external signals and cell anchorage,
trademarks of malignant transformation (14). Therefore, the xenograft primary
tumors depleted of KISS1R expression may have had reduced tumor volume due
to reduced cell proliferation. Thus, a mechanism by which KISS1R may reduce
breast cancer metastasis is by limiting primary tumor growth through
angiogenesis and cell proliferation, thereby reducing the number of cancer cells
available to metastasize.
KISS1R Signaling in Breast Cancer Invasion and Migration
For our study, we used two human breast cancer cell lines, MDA-MB-231
and Hs578T. These cell lines endogenously express KISS1R and EGFR, and
kisspeptin-10 stimulation of these cells promotes migration and invasion (7, 8,
15, 16). Our study extended these findings by demonstrating that depletion of
KISS1R expression reduces breast cancer cells capacity to form stress fiber
formation. Similarly, our findings showed that KISS1R depletion reduces cellular
migration as assessed through scratch and transwell migration assays
supporting a role for KISS1R signaling in breast cancer cell migration. However,
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kisspeptin-10 treatment was only able to significantly increase migration as
assessed in the transwell chamber migration assay but not the scratch assay,
possibly due to the scratch assay’s lack of a chemical gradient as established in
the transwell chamber assay (Supplementary Figure 1)(17).
The ability of cancer cells to acquire a migratory phenotype is thought to
occur through EMT. Previous findings in our lab have demonstrated that
exogenous expression of KISS1R in MCF10A breast epithelial cells or SKBR3
breast cancer cells initiated an EMT process, leading to increased expression of
mesenchymal markers Snail/Slug, N-cadherin, and vimentin (7). In this study, we
observed that depletion of KISS1R in MDA-MB-231 and Hs578T cells decreased
expression of mesenchymal markers Snail/Slug, β-catenin, and smooth muscle
actin. Lastly, our findings supported a role for KISS1R in breast cancer invasion
by demonstrating that depletion of KISS1R expression resulted in decreased
invasion of MDA-MB-231 and Hs578T cells in the transwell Matrigel invasion and
the 3D-Matrigel invasion assays. High expression of mesenchymal markers in
cancer cells, leading to cell invasion and migration, has been linked to increased
cancer progression and metastasis (18). Our results support a role for KISS1R
signaling in the promotion EMT, migration and invasion of breast cancer cells,
thus conceivably contributing to the amount of lung metastases we observed in
our xenograft mouse model.
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KISS1R Signaling in Invadopodia Formation
Over the last decade, significant progress has been made in
understanding the role of invadopodia in cell invasion and its contribution to
cancer metastasis. First implicated in focal invasion of cells, invadopodia have
been demonstrated to play a significant role in many metastatic events as
revealed through in vivo studies. Invadopodia formation has been directly shown
to be involved in cancer cell invasion into the basement membrane surrounding
primary tumors as well as playing a direct role in cancer cell intravasation and
extravasation (19, 20). Thus, understanding how invadopodia formation occurs
and which proteins control invadopodia establishment and invasion is essential
for understanding the events that regulate cancer metastasis. Previous studies
have revealed that two proteins, cortactin and cofilin, are major invadopodia
precursors that control invadopodia formation and maturity. Upon stimulation of
growth factors, such as lysophosphatidic acid (LPA) or EGF, a cascade of
signaling

leads

to

increased

activity

of

cofilin

and

cortactin

through

dephosphorylation of Serine 3 and Tyrosine 421, respectively (21-23). Growth
factor stimulation has been shown to influence the phosphorylation status of
cofilin and cortactin as quick as 30 seconds to as long as a hour, with peak times
within the 3-15 minute range (20, 24, 25). Therefore, for our study we stimulated
MDA-MB-231 cells with kisspeptin-10 for 5 and 15 minutes and observed for
subsequent changes in phosphorylation of cortactin and cofilin. Upon kisspeptin10 stimulation we saw a peak dephosphorylation of cofilin at 15 minutes and
cortactin at 5 minutes after stimulation. However, to directly determine if
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kisspeptin signaling is involved in invadopodia formation, we used gelatin
degradation assays, the gold standard assay, to quantify invadopodia formation
in numerous cells (19, 20, 24, 26-28). Changes to invadopodia formation due to
growth factor stimulation has been demonstrated to take 15 minutes to 3 hours,
depending largely on cell type (29, 30). Upon stimulation with kisspeptin-10 we
observed peak invadopodia formation at 30 minutes, thus all subsequent
experiments

were

performed

with

30

minute

kisspeptin-10

stimulation

(Supplementary Figure 2). Overall, these results suggest that kisspeptin/KISS1R
signaling can promote the formation of invadopodia in human breast cancer cells.
Invadopodia maturation occurs through several stages of protein
localization and activity (31). Changes in cortactin and cofilin activity only account
for the initial stage of invadopodia formation and protrusion. At maturation, MT1MMP co-localizes at the invadopodia tip and mediates ECM remodeling (31, 32).
Phosphorylation of MT1-MMP at tyrosine 573 regulates protein activity leading to
matrix-degradation resulting in cell invasion and tumor progression (33-35). We
observed that stimulation with kisspeptin-10 increased tyrosine phosphorylation
of MT1-MMP. In combination with our findings that kisspeptin increases
invadopodia formation and gelatin degradation, the ability of kisspeptin to
increase MT1-MMP tyrosine phosphorylation supports the previous studies
implicating MT1-MMP tyrosine phosphorylation increases MT1-MMP invasive
activity (33-35). However, due to the use of a non-specific tyrosine antibody, it is
unknown if the change in tyrosine phosphorylation is that of tyrosine 573 or
another tyrosine residue specific to KISS1R signaling. We have previously
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demonstrated that KISS1R transactivates EGFR leading to invasion through
increased MMP-9 activity (8). MT1-MMP degradation of ECM occurs through
MT1-MMP mediated activation of related MMPs including MMP-9 (36). Hence,
kisspeptin-10 mediated increase in MT1-MMP supports the previous findings that
kisspeptin signaling leads to increase MMP-9 activity (8). Furthermore, we
observed that KISS1R co-localizes with EGFR and MT1-MMP in invadopodia.
Our laboratory has previously shown that KISS1R transactivates EGFR to
mediate breast cancer cell invasion and EGFR has been demonstrated to play
an important role in invadopodia invasion (8, 24). Thus, these results support a
possible role for KISS1R in the formation and function of invadopodia.
The scaffolding protein IQGAP1 is considered an oncogene and has been
shown to promote breast cancer cell tumorigenesis (37, 38). A previous study
investigating MT1-MMP delivery in invadopodia determined that the scaffolding
protein IQGAP1 regulates exocyst complex and MT1-MMP delivery to the
invadopodia tip (39). Our study supported this finding, by observing that IQGAP1
co-localized with MT1-MMP and cortactin in invadopodia. Our laboratory has
previously shown that IQGAP1 co-localizes with KISS1R at the leading edge of
migrating breast cancer cells (7). Furthermore, KISS1R transactivates EGFR in
an IQGAP1 dependent manner (7). In this study, we observed that KISS1R colocalizes with IQGAP1 and MT1-MMP in invadopodia. Hence, KISS1R may
regulate invadopodia invasion through regulation of IQGAP1 mediated MT1MMP delivery as well as regulating MT1-MMP phosphorylation. Overall, our
results suggest that KISS1R signaling regulates the initial stages of invadopodia
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formation through the regulation of cofilin and cortactin activity, as well as
invadopodia maturation through regulation of MT1-MMP activity and delivery.
Due to the evidence for invadopodia in the promotion of metastasis, the ability of
KISS1R to promote invadopodia provides an additional mechanism by which
KISS1R expression may influence breast cancer metastasis as seen in vivo (40,
41).
KISS1R Signals via β-arrestin2 in Invadopodia formation and Extravasation
The scaffolding protein β-arrestin2 is a critical regulator of breast cancer
cell migration and invasion (8, 42, 43). We have previously found β-arrestin2
regulates EGFR transactivation by regulating secretion and activity of MMP-9 (7,
8). Global proteomic analysis has demonstrated that β-arrestins interact directly
with the invadopodia precursors, cofilin and cortactin (44). Additionally in MDAMB-468 breast cancer cells, cofilin activity has shown to be regulated by βarrestin downstream of protease-activated receptor-2 (45). However, whether βarrestins play a role in invadopodia formation and activity is unknown. We
observed that depletion of β-arrestin2 decreased basal levels of invadopodia
formation in MDA-MB-231 breast cancer cells thus supporting a role for βarrestin2 in invadopodia formation. Due to the ability of β-arrestin2 to bind both
cortactin and cofilin and evidence that β-arrestin2 regulates KISS1R signaling,
we investigated if β-arrestin2 regulated kisspeptin-10 mediated cofilin and
cortactin dephosphorylation (44-46). Upon depletion of β-arrestin2, kisspeptin-10
was unable to decrease both cofilin and cortactin phosphorylation. Likewise, we
observed co-localization of β-arrestin2 with MT1-MMP and cortactin during
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invadopodia formation. Thus, for the first time, our results suggest a role for βarrestin2 in kisspeptin-10 mediated invadopodia formation and invasion.
Conclusive evidence has demonstrated that invadopodia are necessary
for cancer intravasation and extravasation, and metastasis in vivo (40, 41). The
chick embryonic chorioallantoic membrane (CAM) is a suitable model for
observing cancer cell extravasation as the CAM microvasculature exhibit a
continuous endothelial layer with an underlying basement membrane (47-49).
Using appropriate visualization equipment, this assay enables the observation of
cancers cells within blood capillaries, cells undergoing extravasation through the
endothelial layer, and cancer cells within stroma (47). Previous findings in our
laboratory have demonstrated that exogenous expression of KISS1R in SKBR3
breast cancer cells alone could significantly increase cell extravasation over
basal levels as observed using the CAM assay (7). Furthermore, treatment of
SKBR3 cells expressing exogenous KISS1R with kisspeptin-10 greatly increased
SKBR3 extravasation which in turn could be inhibited using the KISS1R
antagonist, P-234 (7). Our findings in this study support these previous results
whereas kisspeptin-10 treatment of MDA-MB-231 cells increased extravasation
in the CAM assay, which was in turn inhibited with P-234. Additionally, we found
that the EGFR antagonist, AG1478, was able to inhibit basal and kisspeptin-10
mediated extravasation of MDA-MB-231 cells, thus supporting a role for both
EGFR and KISS1R in breast cancer cell extravasation. Moreover, we found
MDA-MB-231 cells depleted of KISS1R expression had reduced extravasation
compared to basal levels and inhibited kisspeptin-10 mediated extravasation.
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Finally, we observed that β-arrestin2 depletion significantly reduced breast
cancer cell extravasation below basal levels and inhibited kisspeptin-10
stimulated extravasation increase. These results demonstrate that KISS1R
signaling contributes to breast cancer cell extravasation through a β-arrestin2
dependent mechanism. Thus, in combination with our findings that KISS1R
signaling plays a role in invadopodia formation and activity, it is possible that
cancer cells with decreased KISS1R or β-arrestin2 expression are unable to form
invadopodia which in turn inhibits extravasation and metastasis.
3.3 Future Directions
Our research has revealed a possible mechanism by which KISS1R
signaling via β-arrestin2 promotes invadopodia formation (Figure 3.1). However,
further research must be performed to fully understand kisspeptin-10 mediated
effects of invadopodia precursor activity and localization. Previous studies, have
reported conflicting roles for the phosphorylation status of cortactin and
subsequent invadopodia activity. Several studies have reported that increase in
Src mediated cortactin phosphorylation at residue Y421 is required for
invadopodia activity (24, 25, 27). We observed that kisspeptin-10 stimulation
caused a decrease in cortactin Y421 phosphorylation leading to increased
invadopodia formation. These findings suggest that decreased cortactin
phosphorylation is associated with increased cortactin activity which has also
been reported by two previous studies, Martinez-Quiles et al. (2004) and Meiler
et al. (2012) (21, 22). Martinez-Quiles et al. (2004) demonstrated that
extracellular-regulated

kinase

(ERK)

induces

cortactin

serine/threonine
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phosphorylation necessary for cortactin N-WASP binding and ensuing actin
polymerization. Consequently, Src phosphorylation of cortactin residue Y421
inhibited the ability of cortactin to bind to N-WASP and promote actin
polymerization (21).
It has been established that KISS1R signaling leads to β-arrestin2
dependent activation of ERK1/2 (15, 50). Our laboratory has previously
demonstrated that kisspeptin-10 stimulation causes transactivation of EGFR, a
well-known ERK activator (8, 51). Additionally, EGFR has been reported to bind
to and increase activity of protein tyrosine phosphatase 1B (PTP1B), the
phosphatase that causes dephosphorylation of cortactin Y421 (52, 53).
Therefore, it is possible that kisspeptin-10 stimulation may lead to ERK activity
though β-arrestin2 or EGFR transactivation, leading to subsequent cortactin
mediated invadopodia formation. Hence, further research must be performed to
evaluate such a mechanism, specifically whether kisspeptin-10 signaling leads to
increased ERK and PTP1B activity in breast cancer cells.
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Figure 3.1 Proposed mechanism of KISS1R mediated invadopodia
formation. This study (green lines) revealed that kisspeptin-10 stimulation of
KISS1R increases cortactin and cofilin activity via β-arrestin2. Previous work in
the Bhattacharya laboratory (red lines) has demonstrated that KISS1R
transactivates EGFR via a β-arrestin2 dependent mechanism. Consequently,
kisspeptin-10 signaling may lead to ERK and PTP1B activity, subsequent
cortactin mediated actin polymerization and invadopodia formation.
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3.4 Conclusion
Our results demonstrate for the first time that KISS1R signaling regulates
human breast cancer metastasis. In vitro and in vivo experimentation has
demonstrated that KISS1R expression plays a role in events that both regulate
breast primary tumor development, such as angiogenesis, as well as events that
that dictate metastasis, such as invadopodia formation and extravasation.
Identifying KISS1R as a regulator of these events poses an intriguing therapeutic
possibility; developing a therapeutic to inhibit KISS1R signaling or expression
could both decrease breast primary tumor progression as well as inhibit breast
cancer metastasis. Thus, this study has identified KISS1R as a novel therapeutic
target for prevention of human breast cancer metastasis.
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Supplementary Figures

Supplementary Figure 1. Kisspeptin-10 stimulation did not affect scratch
wound closure. Treatment with kisspeptin-10 100 nM did not significantly
increase migration of MDA-MB-231 breast cancer cells as assessed using the
scratch assay (n=4).

Supplementary Figure 2. Kisspeptin-10 stimulation causes peak
invadopodia formation at 30 minutes. MDA-MB-231 breast cancer cells
treated with kisspeptin-10 100 nM caused increased invadopodia formation at 30
and 60 minutes (n=3-6). One-way ANOVA followed by Dunnett’s multiple
comparison test: *, P < 0.05. Columns represent percent of cells with
invadopodia ± SEM.
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